
  
    
      
        Background_NNP
        Whole-genome_NNP expression_NN profiling_VBG exemplified_VBN by_IN the_DT
        development_NN of_IN DNA_NNP microarrays_NNS represents_VBZ a_DT major_JJ advance_NN
        in_IN genome-wide_JJ functional_JJ analysis_NN [_NN 1_CD 2_CD ]_NN ._. In_IN a_DT single_JJ
        assay_NN ,_, the_DT transcriptional_NN response_NN of_IN each_DT gene_NN to_TO a_DT
        change_NN in_IN cellular_JJ state_NN can_MD be_VB measured_VBN ,_, whether_IN it_PRP is_VBZ a_DT
        viral_JJ infection_NN ,_, host_NN cell_NN cycle_NN changes_NNS ,_, chemical_NN
        treatment_NN ,_, or_CC genetic_JJ perturbation_NN ._. Specifically_RB ,_,
        systematic_JJ approaches_NNS for_IN identifying_VBG the_DT biological_JJ
        functions_NNS of_IN cellular_JJ genes_NNS altered_VBN during_IN these_DT changes_NNS ,_,
        such_JJ as_IN HIV-_NNP 1_CD infection_NN ,_, are_VBP needed_VBN to_TO ensure_VB rapid_JJ
        progress_NN in_IN defining_VBG significant_JJ host_NN and_CC viral_JJ genome_NN
        sequences_NNS in_IN directed_VBN experimentation_NN and_CC applications_NNS ._.
        Therefore_RB ,_, host_NN cellular_JJ states_NNS can_MD be_VB inferred_VBN from_IN the_DT
        expression_NN profiles_NNS ,_, and_CC the_DT notion_NN that_IN the_DT global_JJ
        transcriptional_NN response_NN constitutes_VBZ a_DT detailed_VBN molecular_JJ
        phenotype_NN ,_, such_JJ as_IN class_NN discovery_NN ,_, class_NN prediction_NN ,_, drug_NN
        target_NN validation_NN ,_, and_CC the_DT classification_NN of_IN tumors_NNS by_IN
        expression_NN profiling_VBG has_VBZ begun_VBN to_TO receive_VB considerable_JJ
        attention_NN [_NN 3_CD 4_CD 5_CD 6_CD 7_CD 8_CD 9_CD 10_CD 11_CD ]_NN ._.
        Since_IN its_PRP$ discovery_NN ,_, much_JJ of_IN the_DT mainstream_NN human_JJ
        immunodeficiency_NN virus_NN type_NN 1_CD (_( HIV-_NNP 1_LS )_) Tat_NNP research_NN has_VBZ
        focused_VBN on_IN its_PRP$ ability_NN to_TO activate_VBP the_DT HIV-_NNP 1_CD LTR_NNP ._. However_RB ,_,
        to_TO date_NN ,_, besides_IN the_DT transactivation_NN activity_NN on_IN the_DT HIV-_NNP 1_CD
        promoter_NN ,_, few_JJ other_JJ effects_NNS exerted_VBN by_IN HIV-_NNP 1_CD Tat_NNP on_IN
        cellular_JJ and_CC viral_JJ genes_NNS has_VBZ also_RB been_VBN observed_VBN ._. The_DT Tat_NNP
        protein_NN has_VBZ been_VBN shown_VBN to_TO transcriptionally_RB repress_NNS host_NN
        cellular_JJ genes_NNS and_CC be_VB involved_VBN in_IN the_DT immunosuppression_NN
        associated_VBN with_IN viral_JJ infection_NN ._. For_IN instance_NN ,_, HIV-_NNP 1_CD
        infection_NN is_VBZ able_JJ to_TO down-regulate_JJ major_JJ histocompatibility_NN
        complex_JJ type_NN I_PRP (_( MHC-I_NNP )_) by_IN various_JJ different_JJ viral_JJ proteins_NNS ,_,
        including_VBG Tat_NNP which_WDT represses_NNS the_DT transcription_NN of_IN MHC-I_NNP ,_,
        Vpu_NNP which_WDT retains_VBZ nascent_NN MHC-I_NNP chains_NNS in_IN the_DT endoplasmic_JJ
        reticulum_NN ,_, and_CC Nef_NNP which_WDT can_MD mediate_VB selective_JJ
        internalization_NN of_IN MHC-I_NNP molecules_NNS from_IN the_DT plasma_NN
        membrane_NN ._. MHC_NNP class_NN I_PRP gene_NN expression_NN has_VBZ also_RB been_VBN shown_VBN
        to_TO be_VB reduced_VBN upon_IN infection_NN with_IN the_DT wild-type_JJ LAI_NNP virus_NN
        or_CC a_DT Tat_NNP exon_NN one_CD recombinant_JJ virus_NN [_NN 12_CD 13_CD ]_NN ._.
        Tat_NNP has_VBZ been_VBN shown_VBN to_TO down-regulate_JJ mannose_NN receptor_NN ,_,
        EDF-_NNP 1_CD ,_, CD_NNP 3_CD -_: gamma_NN ,_, and_CC TCR_NNP /_NN CD_NNP 3_CD surface_NN receptor_NN [_NN 14_CD ]_NN ._. Tat_NNP
        reduces_VBZ mannose_NN receptor_NN levels_NNS and_CC promoter_NN activity_NN in_IN
        mature_VBP macrophages_NNS and_CC dendritic_JJ cells_NNS by_IN interfering_VBG with_IN
        the_DT host_NN transcriptional_NN machinery_NN ;_: resulting_VBG in_IN decreased_VBD
        levels_NNS of_IN surface_NN mannose_NN receptor_NN needed_VBN for_IN Ag_NNP
        (_( mannosylated_JJ albumin_NN uptake_NN )_) or_CC pathogen_NN capture_NN
        (_( Pneumocystis_NNP carinii_NN phagocytosis_NNS )_) ,_, and_CC eventual_JJ delivery_NN
        to_TO MHC_NNP class_NN II-containing_NNP intracellular_NN compartments_NNS [_NN 15_CD
        ]_NN ._. EDF-_NNP 1_CD ,_, a_DT gene_NN down-regulated_JJ when_WRB endothelial_NN cells_NNS are_VBP
        induced_VBN to_TO differentiate_VB 
        in_IN vitro_NN ,_, was_VBD shown_VBN to_TO be_VB
        down-regulated_JJ by_IN Tat_NNP at_IN the_DT transcriptional_NN level_NN ,_,
        resulting_VBG in_IN the_DT inhibition_NN of_IN endothelial_NN cell_NN growth_NN and_CC
        in_IN the_DT transition_NN from_IN a_DT nonpolar_NN cobblestone_NN phenotype_NN to_TO
        a_DT polar_JJ fibroblast-like_JJ phenotype_NN [_NN 16_CD ]_NN ._.
        When_WRB examining_VBG the_DT 
        in_IN vivo_NN effects_NNS of_IN HIV-_NNP 1_CD Tat_NNP protein_NN
        in_IN the_DT 
        Xenopus_NNP embryo_NN ,_, it_PRP was_VBD found_VBN that_IN
        upon_IN injection_NN of_IN synthetic_JJ Tat_NNP mRNA_NN into_IN zygotes_NNS ,_, a_DT marked_VBN
        delay_NN in_IN gastrulation_NN occurred_VBD ._. This_DT led_VBN to_TO the_DT altered_VBN
        specification_NN of_IN the_DT anterior-posterior_JJ axis_NNS and_CC partial_JJ
        loss_NN of_IN the_DT anterior_NN embryo_NN structures_NNS ._. Mechanistically_NNP ,_,
        HIV-_NNP 1_CD Tat_NNP elicited_JJ a_DT general_JJ suppression_NN of_IN gene_NN
        expression_NN ,_, including_VBG that_IN of_IN 
        Xbra_NNP and_CC 
        gsc_NN ,_, two_CD early_JJ genes_NNS whose_WP$
        expression_NN are_VBP required_VBN for_IN proper_JJ gastrulation_NN [_NN 17_CD ]_NN
        ._.
        In_IN relation_NN to_TO the_DT cell_NN cycle_NN ,_, Tat_NNP has_VBZ also_RB been_VBN shown_VBN
        to_TO bind_NN to_TO p_NN 53_CD and_CC inhibit_VB the_DT transcription_NN of_IN p_NN 53_CD
        responsive_JJ elements_NNS ,_, such_JJ as_IN the_DT p_NN 21_CD /_NN Waf_NNP 1_CD gene_NN promoter_NN ._.
        Consequently_RB ,_, upon_IN introduction_NN of_IN stress_NN signals_NNS (_( e_SYM ._. g_SYM ._. ,_,
        gamma_NN irradiation_NN )_) ,_, HIV-_NNP 1_CD -_: infected_JJ cells_NNS lose_VBP their_PRP$ G_NNP 1_CD /_NN S_NNP
        checkpoint_NN ,_, enter_VBP the_DT S-_NNP phase_NN inappropriately_RB ,_, and_CC apoptose_NN
        [_NN 18_CD 19_CD 20_CD ]_NN ._. Finally_RB ,_, the_DT inhibition_NN of_IN Tat_NNP on_IN
        translational_NN machinery_NN has_VBZ also_RB been_VBN noted_VBN ._. The_DT potential_JJ
        translational_NN inhibitory_NN effects_NNS of_IN the_DT TAR_NNP RNA_NNP region_NN is_VBZ
        mediated_JJ by_IN the_DT activation_NN of_IN p_NN 68_CD (_( the_DT interferon-induced_JJ
        68_CD -_: kilodalton_NN protein_NN kinase_NN )_) kinase_NN ,_, which_WDT was_VBD
        down-regulated_JJ by_IN Tat_NNP during_IN productive_JJ HIV-_NNP 1_CD infection_NN [_NN
        22_CD ]_NN ._.
        Although_IN the_DT mechanism_NN of_IN the_DT host_NN cellular_JJ
        down-regulation_JJ remains_VBZ largely_RB unknown_JJ ,_, few_JJ reports_NNS have_VBP
        attempted_VBN to_TO decipher_NN the_DT mechanism_NN of_IN the_DT observed_VBN
        inhibition_NN ._. For_IN instance_NN ,_, the_DT addition_NN of_IN Tat_NNP to_TO PC_NN 12_CD cells_NNS
        up-regulated_JJ the_DT expression_NN of_IN the_DT inducible_JJ cAMP_NN early_JJ
        repressor_NN (_( ICER_NNP )_) ,_, a_DT specific_JJ member_NN of_IN the_DT cAMP-responsive_JJ
        element_NN modulator_NN transcription_NN factor_NN family_NN ,_, in_IN a_DT
        cAMP-dependent_JJ manner_NN ._. In_IN turn_NN ,_, ICER_NNP overexpression_NN
        abrogated_JJ the_DT transcriptional_NN activity_NN of_IN the_DT TH_NNP promoter_NN ,_,
        strongly_RB suggesting_VBG ICER_NNP 's_POS involvement_NN in_IN Tat-mediated_NNP
        inhibition_NN of_IN gene_NN expression_NN [_NN 23_CD ]_NN ._.
        Aside_RB from_IN induction_NN of_IN ICER_NNP ,_, Tat_NNP is_VBZ capable_JJ of_IN forming_VBG
        complex_JJ (_( es_NNS )_) with_IN a_DT component_NN of_IN TFIID_NNP ,_, TAF_NNP 
        II_NNP 250_CD [_NN 24_CD ]_NN and_CC Tip_NNP 60_CD [_NN 25_CD ]_NN both_DT of_IN
        which_WDT contain_VBP histone_NN acetyltransferase_NN (_( HAT_NNP )_) activity_NN ._. In_IN
        these_DT cases_NNS ,_, Tat-_NNP TAF_NNP 
        II_NNP 250_CD and_CC Tat-_NNP Tip_NNP 60_CD do_VBP not_RB affect_VB the_DT
        transcription_NN from_IN the_DT HIV-_NNP 1_CD LTR_NNP ,_, but_CC interfere_VB with_IN the_DT
        transcription_NN activity_NN of_IN cellular_JJ genes_NNS ._. It_PRP is_VBZ postulated_JJ
        that_IN different_JJ targets_NNS of_IN HATs_NNP by_IN Tat_NNP have_VBP different_JJ
        consequences_NNS ._. The_DT interaction_NN of_IN Tat_NNP with_IN p_NN 300_CD /_NN CBP_NNP and_CC
        P_NN /_NN CAF_NNP stimulates_NNS its_PRP$ ability_NN to_TO transactivate_NN LTR-dependent_NNP
        transcription_NN ,_, while_IN Tat-_NNP TAF_NNP 
        II_NNP 250_CD or_CC Tat-_NNP Tip_NNP 60_CD interactions_NNS control_VBP
        the_DT transcription_NN of_IN cellular_JJ genes_NNS ._.
        Here_RB to_TO better_JJR understand_VB the_DT host_NN response_NN to_TO Tat_NNP ,_, we_PRP
        have_VBP performed_VBN microarray_NN experiments_NNS on_IN HIV-_NNP 1_CD infected_JJ
        cells_NNS expressing_VBG the_DT Tat_NNP protein_NN ._. To_TO our_PRP$ surprise_NN many_JJ host_NN
        cellular_JJ genes_NNS were_VBD down-regulated_JJ when_WRB comparing_VBG HIV-_NNP 1_CD
        infected_JJ latent_NN cells_NNS to_TO uninfected_JJ parental_JJ cells_NNS ._. Because_IN
        most_JJS ,_, if_IN not_RB all_DT ,_, latent_NN infected_JJ cells_NNS available_JJ to_TO date_NN
        (_( e_SYM ._. g_SYM ._. ,_, ACH_NNP 2_CD ,_, U_NNP 1_CD ,_, J_NNP 1_CD ._. 1_LS ,_, OM_NNP ._. 10_CD )_) have_VBP various_JJ expression_NN
        levels_NNS of_IN doubly_RB spliced_JJ viral_JJ mRNAs_NNS ,_, including_VBG Tat_NNP ,_, Rev_NNP ,_,
        Nef_NNP ,_, Vpr_NNP ,_, and_CC other_JJ accessory_JJ proteins_NNS ,_, we_PRP decided_VBD to_TO
        perform_VB the_DT microarray_NN in_IN a_DT system_NN where_WRB Tat_NNP was_VBD
        constitutively_RB expressed_VBN ;_: asking_VBG whether_IN Tat_NNP by_IN itself_PRP ,_, or_CC
        in_IN the_DT absence_NN of_IN other_JJ accessory_JJ proteins_NNS ,_, could_MD still_RB
        down-regulate_JJ host_NN cellular_JJ genes_NNS ._. Consistent_NNP with_IN latently_RB
        infected_JJ cells_NNS ,_, we_PRP found_VBD many_JJ cellular_JJ genes_NNS to_TO be_VB
        down-regulated_JJ in_IN Tat_NNP expressing_VBG lymphocytes_NNS ._. The_DT
        down-regulation_JJ is_VBZ most_RBS apparent_JJ on_IN cellular_JJ receptors_NNS that_WDT
        have_VBP intrinsic_JJ receptor_NN tyrosine_NN kinase_NN (_( RTK_NNP )_) activity_NN and_CC
        signal_NN transduction_NN members_NNS that_WDT mediate_VB RTK_NNP function_NN ;_:
        including_VBG the_DT Ras-_NNP Raf-_NNP MEK_NNP pathway_NN ,_, and_CC co-activators_JJ such_JJ
        as_IN p_NN 300_CD /_NN CBP_NNP and_CC SRC-_NNP 1_CD ,_, which_WDT mediate_VB gene_NN expression_NN
        related_VBN to_TO hormone_NN receptor_NN genes_NNS ._. Interestingly_RB ,_, we_PRP also_RB
        observed_VBD up-regulation_JJ of_IN S-_NNP phase_NN genes_NNS ,_, as_RB well_RB as_IN
        ribosomal_JJ genes_NNS involved_VBN in_IN translation_NN ._. Functionally_NNP ,_,
        down-regulation_JJ of_IN receptors_NNS may_MD allow_VB latent_NN HIV-_NNP 1_CD
        infected_JJ cells_NNS to_TO either_CC hide_VB from_IN the_DT immune_JJ system_NN or_CC
        avoid_VB extracellular_NN differentiation_NN signals_NNS normally_RB
        regulated_VBN by_IN receptors_NNS ._. Up-regulation_NNP of_IN S-_NNP phase_NN and_CC
        translation_NN genes_NNS may_MD allow_VB speeding_NN of_IN cells_NNS through_IN the_DT
        S-_NNP phase_NN and_CC subsequent_JJ accumulation_NN at_IN the_DT G_NNP 2_CD phase_NN ,_, where_WRB
        most_JJS of_IN the_DT cellular_JJ and_CC viral_JJ translation_NN may_MD take_VB place_NN ._.
        Therefore_RB ,_, the_DT presence_NN of_IN Tat_NNP may_MD not_RB only_RB control_VB
        activated_VBN transcription_NN on_IN HIV-_NNP 1_CD LTR_NNP ,_, but_CC also_RB aid_VB in_IN the_DT
        subsequent_JJ translation_NN of_IN viral_JJ mRNA_NN in_IN the_DT cytoplasm_NN ._.
      
      
        Results_NNS and_CC discussion_NN
        
          Receptor_NNP family_NN members_NNS
          It_PRP has_VBZ long_RB been_VBN known_VBN that_DT infection_NN by_IN HIV-_NNP 1_CD
          commonly_RB leads_VBZ to_TO the_DT down-regulation_JJ and_CC the_DT
          disappearance_NN of_IN CD_NNP 4_CD receptors_NNS from_IN the_DT plasma_NN membrane_NN ,_,
          a_DT phenomenon_NN referred_VBD to_TO as_IN receptor_NN down-modulation_JJ ._.
          This_DT ,_, in_IN turn_NN ,_, renders_NNS cells_NNS refractory_JJ to_TO subsequent_JJ
          infection_NN by_IN the_DT same_JJ or_CC other_JJ viruses_NNS that_WDT use_NN the_DT CD_NNP 4_CD
          receptor_NN for_IN entry_NN ;_: thus_RB creating_VBG a_DT state_NN of_IN
          super-infection_JJ immunity_NN ._. Results_NNS in_IN Table_NNP 1_CD indicate_VBP that_IN
          although_IN few_JJ receptor_NN genes_NNS were_VBD up-regulated_JJ ,_, most_JJS of_IN
          the_DT cellular_JJ receptors_NNS in_IN general_NN ,_, were_VBD down-regulated_JJ in_IN
          the_DT presence_NN of_IN the_DT Tat_NNP protein_NN ._. Most_JJS of_IN these_DT receptors_NNS
          or_CC membranous_JJ proteins_NNS were_VBD initially_RB discovered_VBN from_IN
          immune_JJ or_CC neuronal_NN cells_NNS ,_, hence_RB they_PRP were_VBD given_VBN names_NNS
          related_VBN to_TO the_DT immune_JJ or_CC nervous_JJ system_NN ._. For_IN instance_NN ,_,
          mRNA_NN for_IN the_DT neuropeptide_NN Y-_NNP like_IN receptor_NN (_( Acc_NNP #_# X_NNP 71635_CD )_) ,_,
          which_WDT was_VBD up-regulated_JJ in_IN Tat_NNP expressing_VBG cells_NNS ,_, was_VBD
          initially_RB discovered_VBN as_IN a_DT G-_NNP protein_NN coupled_VBN neuropeptide_NN
          Y_NNP receptor_NN ,_, and_CC later_RB found_VBD to_TO be_VB homologous_RB to_TO the_DT
          co-receptor_JJ CCR_NNP 5_CD needed_VBN for_IN HIV-_NNP 1_CD infection_NN of_IN
          monocyte_NN /_NN macrophage_NN cells_NNS ._. Therefore_RB ,_, most_JJS of_IN the_DT
          receptors_NNS listed_VBN in_IN Table_NNP 1_CD may_MD in_IN fact_NN be_VB expressed_VBN in_IN
          various_JJ tissues_NNS and_CC have_VBP multiple_JJ functions_NNS ._.
          Consistent_NNP with_IN our_PRP$ microarray_NN results_NNS on_IN CCR_NNP 5_CD
          up-regulation_JJ ,_, experiments_NNS performed_VBN in_IN peripheral_JJ blood_NN
          mononuclear_NN cells_NNS (_( PBMCs_NNP )_) with_IN soluble_JJ Tat_NNP has_VBZ shown_VBN
          selective_JJ entry_NN and_CC replication_NN of_IN CCR_NNP 5_CD virus_NN into_IN cells_NNS
          [_NN 27_CD 28_CD ]_NN ._. Up-regulation_NNP of_IN HIV-_NNP 1_CD coreceptor_NN by_IN Tat_NNP has_VBZ
          also_RB been_VBN reported_VBN ,_, where_WRB a_DT synthetic_JJ Tat_NNP protein_NN that_WDT
          was_VBD immobilized_JJ on_IN a_DT solid_JJ substrate_NN ,_, up-regulated_JJ the_DT
          surface_NN expression_NN of_IN the_DT chemokine_NN receptors_NNS in_IN purified_JJ
          populations_NNS of_IN primary_JJ resting_VBG CD_NNP 4_CD +_NN T_NN cells_NNS ._. Also_RB ,_, a_DT
          similar_JJ result_NN was_VBD seen_VBN from_IN Tat_NNP protein_NN actively_RB
          released_VBN by_IN HIV-_NNP 1_CD infected_JJ cells_NNS ,_, implying_VBG a_DT potentially_RB
          important_JJ role_NN for_IN extracellular_NN Tat_NNP in_IN rendering_VBG the_DT
          bystander_NN CD_NNP 4_CD +_NN T_NN cells_NNS more_RBR susceptible_JJ to_TO infection_NN [_NN 28_CD
          ]_NN ._.
          We_PRP therefore_RB tested_VBD whether_IN H_NNP 9_CD /_NN Tat_NNP cells_NNS ,_, which_WDT showed_VBD
          an_DT increase_NN in_IN CCR_NNP 5_CD expression_NN ,_, could_MD in_IN fact_NN allow_VB
          better_JJR entry_NN and_CC infection_NN of_IN the_DT CCR_NNP 5_CD (_( R_NN 5_LS )_) virus_NN into_IN
          cells_NNS ._. Figure_NN 3_CD Ashows_NNP the_DT result_NN of_IN such_JJ an_DT experiment_NN ,_,
          where_WRB H_NNP 9_CD /_NN Tat_NNP cells_NNS allowed_VBD a_DT better_RB replication_NN profile_NN
          of_IN the_DT R_NN 5_CD than_IN the_DT CXCR_NNP 4_CD (_( X_NNP 4_LS )_) virus_NN ._. The_DT increase_NN in_IN
          viral_JJ titer_NN peaked_VBD after_IN some_DT 18_CD days_NNS of_IN infection_NN with_IN
          the_DT R_NN 5_CD virus_NN ,_, further_JJ implying_VBG that_IN the_DT CCR_NNP 5_CD co-receptor_JJ
          allowed_VBD a_DT better_RB selection_NN of_IN R_NN 5_CD virus_NN in_IN Tat_NNP expressing_VBG
          cells_NNS ._.
          Another_DT example_NN of_IN co-receptors_JJ with_IN multiple_JJ
          functions_NNS is_VBZ the_DT leukotriene_NN family_NN member_NN B_NNP 4_CD ,_, which_WDT was_VBD
          down-regulated_JJ in_IN Tat_NNP expressing_VBG cells_NNS (_( Acc_NNP #_# D_NNP 89078_CD ,_,
          Table_NNP 1_LS )_) ._. The_DT cysteinyl_NN leukotrienes_NNS (_( CysLT_NNP )_) ,_, LTC_NNP ,_, LTD_NNP ,_,
          and_CC LTE_NNP ,_, were_VBD first_RB shown_VBN to_TO be_VB essential_JJ mediators_NNS in_IN
          asthma_NN [_NN 29_CD ]_NN ._. However_RB ,_, when_WRB the_DT mouse_NN leukotriene_NN B_NNP 4_CD
          receptor_NN (_( m-_NN BLTR_NNP )_) gene_NN ,_, was_VBD cloned_VBN it_PRP was_VBD shown_VBN to_TO have_VB
          significant_JJ sequence_NN homology_NN with_IN chemokine_NN receptors_NNS
          (_( CCR_NNP 5_CD and_CC CXCR_NNP 4_LS )_) ,_, co-receptors_JJ for_IN many_JJ different_JJ HIV-_NNP 1_CD
          clades_NNS [_NN 30_CD ]_NN ._. Along_IN the_DT same_JJ lines_NNS ,_, when_WRB cells_NNS were_VBD
          infected_VBN with_IN 10_CD primary_JJ clinical_JJ isolates_VBZ of_IN HIV-_NNP 1_CD ,_,
          leukotriene_NN B_NNP 4_CD receptor_NN was_VBD primarily_RB utilized_JJ for_IN
          efficient_JJ entry_NN into_IN cells_NNS which_WDT were_VBD mainly_RB of_IN the_DT
          syncytium-inducing_JJ phenotype_NN [_NN 31_CD ]_NN ._. Therefore_RB ,_,
          up-regulation_JJ of_IN neuropeptide_NN Y-_NNP like_IN receptor_NN and_CC
          down-regulation_JJ of_IN leukotriene_NN B_NNP 4_CD receptor_NN in_IN Tat_NNP
          expressing_VBG cells_NNS indicates_VBZ a_DT selective_JJ advantage_NN of_IN one_CD
          class_NN of_IN virus_NN (_( CCR_NNP 5_LS )_) over_IN another_DT (_( CXCR_NNP 4_LS )_) ._.
          Other_JJ examples_NNS of_IN consistency_NN between_IN our_PRP$ microarray_NN
          results_NNS on_IN receptors_NNS and_CC the_DT HIV-_NNP 1_CD Tat_NNP literature_NN ,_,
          include_VBP the_DT down-regulation_JJ of_IN gene_NN expression_NN in_IN uPAR_NN
          (_( Acc_NNP #_# X_NNP 74039_CD )_) ,_, IP_NNP 3_CD (_( Acc_NNP #_# D_NNP 26070_CD ,_, D_NNP 26351_CD )_) ,_, Glu_NNP R_NNP flop_NN
          (_( Acc_NNP #_# U_NNP 10302_CD )_) ,_, PPAR_NNP (_( Acc_NNP #_# L_NNP 07592_CD )_) ,_, alpha-_NN 2_CD macroglobulin_NN
          receptor_NN protein_NN (_( Acc_NNP #_# M_NNP 63959_CD )_) ,_, and_CC receptor_NN tyrosine_NN
          kinase_NN (_( Acc_NNP #_# L_NNP 36645_CD ,_, U_NNP 66406_CD )_) genes_NNS ._.
          The_DT transmembranous_JJ urokinase-type_JJ plasminogen_NN
          activator_NN receptor_NN (_( uPAR_NN ;_: CD_NNP 87_CD )_) focuses_VBZ the_DT formation_NN of_IN
          active_JJ plasmin_NN at_IN the_DT cell_NN surface_NN ,_, thus_RB enhancing_VBG
          directional_NN extracellular_NN proteolysis_NNS ._. Interestingly_RB ,_, the_DT
          promoter_NN activity_NN of_IN the_DT CD_NNP 87_CD gene_NN was_VBD shown_VBN to_TO decline_VB
          after_IN infection_NN [_NN 32_CD ]_NN ,_, implying_VBG that_DT post_NN integration_NN
          of_IN HIV-_NNP 1_CD may_MD in_IN fact_NN down-regulate_JJ CD_NNP 87_CD gene_NN expression_NN ._.
          Similarly_RB ,_, inositol_NN 1_CD ,_, 4_CD ,_, 5_CD -_: trisphosphate_NN receptors_NNS (_( IP_NNP 3_CD R_NN )_)
          are_VBP intracellular_NN calcium_NN release_NN channels_NNS involved_VBN in_IN
          diverse_JJ signaling_VBG pathways_NNS and_CC are_VBP required_VBN for_IN the_DT
          activation_NN of_IN T_NN lymphocytes_NNS [_NN 33_CD ]_NN ._. Tat_NNP (_( also_RB implicated_VBN
          as_IN a_DT neurotoxin_NN )_) has_VBZ been_VBN shown_VBN to_TO release_VB calcium_NN from_IN
          inositol_NN 1_CD ,_, 4_CD ,_, 5_CD -_: trisphosphate_NN (_( IP_NNP 3_LS )_) receptor-regulated_JJ
          stores_NNS in_IN neurons_NNS and_CC astrocytes_NNS causing_VBG premature_JJ
          apoptosis_NNS [_NN 34_CD ]_NN ._. Down-regulation_NNP of_IN IP_NNP 3_CD may_MD therefore_RB
          contribute_VB to_TO viral_JJ latency_NN and_CC maintenance_NN of_IN an_DT
          anti-apoptotic_JJ state_NN in_IN cells_NNS ._.
          HIV-_NNP 1_CD infection_NN can_MD cause_VB extensive_JJ neuronal_NN loss_NN and_CC
          clinically_RB ,_, a_DT severe_JJ dementia_NN ._. The_DT cause_NN of_IN the_DT
          neurotoxicity_NN remains_VBZ unclear_JJ as_IN neurons_NNS are_VBP not_RB
          infected_JJ ,_, but_CC the_DT disturbance_NN of_IN glutamate-linked_JJ calcium_NN
          entry_NN has_VBZ been_VBN implicated_VBN ._. It_PRP has_VBZ been_VBN shown_VBN that_IN
          HIV-infected_NNP brain_NN has_VBZ a_DT decrease_NN of_IN mRNA_NN and_CC protein_NN of_IN
          the_DT GluR-A_NNP flop_NN subtype_NN of_IN
          alpha-amino-_JJ 3_CD -_: hydroxy-_NN 5_CD -_: methyl-_NN 4_CD -_: isoxazole_NN propionic_JJ acid_NN
          (_( AMPA_NNP )_) glutamate_NN receptor_NN in_IN cerebellar_NN Purkinje_NNP cells_NNS ._.
          The_DT observed_VBN disturbance_NN of_IN AMPA_NNP receptors_NNS may_MD contribute_VB
          to_TO the_DT neurotoxic_JJ process_NN in_IN other_JJ vulnerable_JJ brain_NN
          regions_NNS and_CC clinically_RB to_TO the_DT development_NN of_IN dementia_NN [_NN
          35_CD ]_NN ._. Interestingly_RB ,_, in_IN a_DT mouse_NN model_NN AMPA_NNP receptors_NNS in_IN
          the_DT cortex_NN ,_, striatum_NN ,_, hippocampus_JJ ,_, and_CC cerebellum_NN
          declined_VBN by_IN 29_CD -_: 50_CD %_NN as_RB early_RB as_IN 8_CD weeks_NNS post-retroviral_JJ
          inoculation_NN ._. Thus_RB ,_, the_DT reduction_NN in_IN AMPA_NNP receptor_NN density_NN
          may_MD contribute_VB to_TO the_DT development_NN of_IN the_DT cognitive_JJ
          abnormalities_NNS associated_VBN with_IN HIV-_NNP 1_CD infection_NN [_NN 36_CD ]_NN
          ._.
          Finally_RB ,_, patients_NNS with_IN AIDS_NNP who_WP are_VBP receiving_VBG therapy_NN
          with_IN HIV-_NNP 1_CD protease_NN inhibitors_NNS have_VBP been_VBN reported_VBN to_TO be_VB
          afflicted_VBN with_IN a_DT syndrome_NN characterized_VBN by_IN lipodystrophy_NN
          (_( fat_JJ redistribution_NN favoring_VBG the_DT accumulation_NN of_IN
          abdominal_NN and_CC cervical_JJ adipose_NN tissue_NN )_) ,_, hyperlipidemia_NN ,_,
          and_CC insulin_NN resistance_NN ._. Potential_JJ mechanisms_NNS for_IN altered_VBN
          adipocyte_NN function_NN include_VBP ,_, direct_JJ binding_JJ to_TO PPARgamma_NNP
          or_CC inhibition_NN of_IN transcription_NN of_IN PPARgamma_NNP promoter_NN [_NN 37_CD
          ]_NN ._. The_DT lipodystrophy_NN syndrome_NN may_MD be_VB a_DT result_NN of_IN the_DT
          inhibition_NN of_IN 2_CD proteins_NNS involved_VBN in_IN lipid_NN metabolism_NN
          that_WDT have_VBP significant_JJ homology_NN to_TO the_DT catalytic_JJ site_NN of_IN
          HIV_NNP proteases_NNS ;_: namely_RB cytoplasmic_JJ retinoic_JJ acid_NN binding_JJ
          protein_NN type_NN 1_CD and_CC low_JJ density_NN
          lipoprotein-receptor-related_JJ protein_NN [_NN 38_CD ]_NN ._. An_DT
          additional_JJ mechanism_NN of_IN PPAR_NNP down-regulation_JJ may_MD be_VB
          related_VBN to_TO Tat_NNP expression_NN in_IN latent_NN cells_NNS ._.
        
        
          Translation_NN associated_VBN factors_NNS
          Viruses_NNP have_VBP evolved_VBN a_DT remarkable_JJ variety_NN of_IN
          strategies_NNS to_TO modulate_VBP the_DT host_NN cell_NN translation_NN
          apparatus_NN with_IN the_DT aim_NN of_IN optimizing_VBG viral_JJ mRNA_NN
          translation_NN and_CC replication_NN ._. For_IN instance_NN ,_, viruses_NNS
          including_VBG Herpes_NNP simplex_NN virus_NN type_NN 1_CD (_( HSV-_NNP 1_LS )_) have_VBP been_VBN
          known_VBN to_TO induce_VB severe_JJ alterations_NNS of_IN the_DT host_NN
          translational_NN apparatus_NN ,_, including_VBG the_DT up-regulation_JJ of_IN
          ribosomal_JJ proteins_NNS and_CC the_DT progressive_JJ association_NN of_IN
          several_JJ nonribosomal_NN proteins_NNS ,_, such_JJ as_IN VP_NNP 19_CD C_NNP ,_, VP_NNP 26_CD ,_, and_CC
          the_DT poly_RB (_( A_DT )_) -_: binding_JJ protein_NN 1_CD (_( PAB_NNP 1_CD P_NN )_) to_TO ribosomes_NNS [_NN 39_CD ]_NN
          ._. In_IN the_DT case_NN of_IN HIV-_NNP 1_CD ,_, approximately_RB one_CD infectious_JJ
          HIV-_NNP 1_CD genome_NN in_IN an_DT infected_JJ cell_NN could_MD be_VB transcribed_JJ and_CC
          translated_VBN into_IN 50_CD ,_, 000_CD to_TO 100_CD ,_, 000_CD physical_JJ particles_NNS [_NN 40_CD
          ]_NN ._. This_DT poses_VBZ an_DT immense_JJ challenge_NN for_IN the_DT virus_NN to_TO be_VB
          able_JJ to_TO transcribe_VBP ,_, splice_NN ,_, transport_NN ,_, and_CC translate_VB its_PRP$
          RNA_NNP into_IN fully_RB packaged_VBN virions_NNS in_IN a_DT timely_JJ fashion_NN ._.
          Therefore_RB ,_, it_PRP would_MD be_VB advantageous_JJ for_IN the_DT virus_NN to_TO set_VB
          the_DT stage_NN for_IN each_DT successive_JJ step_NN necessary_JJ for_IN viral_JJ
          progeny_NN formation_NN ._. One_CD such_JJ event_NN is_VBZ Tat_NNP 's_POS ability_NN to_TO
          control_VB genes_NNS that_WDT aid_NN in_IN translational_NN machinery_NN ._. As_IN
          seen_VBN in_IN Table_NNP 2_CD ,_, many_JJ of_IN the_DT critical_JJ components_NNS of_IN a_DT
          functional_JJ ribosome_NN ,_, including_VBG large_JJ subunits_NNS L_NNP 3_CD ,_, 6_CD ,_, 26_CD ,_,
          31_CD ,_, 38_CD ,_, and_CC 41_CD ,_, as_RB well_RB as_IN S_NNP 6_CD ,_, 12_CD ,_, 20_CD ,_, and_CC 24_CD ,_, and_CC many_JJ
          of_IN the_DT translation_NN initiation_NN factors_NNS are_VBP up-regulated_JJ by_IN
          Tat_NNP ._. This_DT would_MD imply_VB that_IN Tat_NNP up-regulates_JJ many_JJ
          ribosomal_JJ genes_NNS that_WDT may_MD be_VB necessary_JJ to_TO produce_VB
          functional_JJ ribosomes_NNS needed_VBN for_IN viral_JJ mRNA_NN translation_NN ._.
          Therefore_RB ,_, interfering_VBG with_IN translation_NN could_MD provide_VB a_DT
          new_JJ strategy_NN for_IN anti-_NN HIV_NNP treatment_NN ._. Along_IN these_DT lines_NNS ,_,
          when_WRB the_DT aminogylcosides_NNS (_( kanamycin_NN ,_, hygromycin_NN B_NNP ,_,
          paromycin_NN and_CC neomycin_NN )_) due_JJ to_TO their_PRP$ ability_NN to_TO inhibit_VB
          protein_NN synthesis_NN by_IN affecting_VBG ribosomal_JJ fidelity_NN ,_, or_CC
          puromycin_NN because_IN of_IN its_PRP$ competing_VBG ability_NN with_IN tRNAs_NNS for_IN
          binding_VBG on_IN the_DT large_JJ ribosomal_JJ subunit_NN ,_, or_CC cycloheximide_NN
          which_WDT inhibit_VBP the_DT large_JJ ribosomal_JJ subunit_NN by_IN preventing_VBG
          ribosomal_JJ movement_NN along_IN the_DT mRNA_NN ,_, were_VBD used_VBN in_IN active_JJ
          HIV-_NNP 1_CD infection_NN ,_, it_PRP was_VBD found_VBN that_IN both_DT cycloheximide_NN and_CC
          puromycin_NN produced_VBD the_DT greatest_JJS decrease_NN in_IN HIV-_NNP 1_CD
          inhibition_NN ,_, presumably_RB by_IN inhibiting_VBG the_DT large_JJ subunit_NN of_IN
          the_DT ribosome_NN [_NN 41_CD ]_NN ._.
          Translation_NN of_IN HIV-_NNP 1_CD RNAs_NNP pose_VB a_DT challenge_NN since_IN they_PRP
          all_DT contain_VBP a_DT TAR_NNP sequence_NN at_IN their_PRP$ 5_CD '_POS end_NN ._. The_DT
          Tat-responsive_NNP region_NN (_( TAR_NNP )_) of_IN HIV-_NNP 1_CD exhibits_VBZ a_DT
          trans-inhibitory_JJ effect_NN on_IN translation_NN by_IN activating_VBG the_DT
          interferon-induced_JJ 68_CD -_: kilodalton_NN protein_NN kinase_NN ._.
          Productive_NNP infection_NN by_IN HIV-_NNP 1_CD has_VBZ been_VBN shown_VBN to_TO result_VB in_IN
          a_DT significant_JJ decrease_NN in_IN the_DT amount_NN of_IN cellular_JJ p_NN 68_CD
          kinase_NN ._. The_DT steady-state_JJ amount_NN of_IN p_NN 68_CD kinase_NN was_VBD found_VBN
          to_TO be_VB reduced_VBN in_IN cells_NNS stably_RB expressing_VBG Tat_NNP ._. Thus_RB ,_, the_DT
          potential_JJ translational_NN inhibitory_NN effects_NNS of_IN the_DT TAR_NNP RNA_NNP
          region_NN ,_, mediated_JJ by_IN activation_NN of_IN p_NN 68_CD kinase_NN ,_, may_MD be_VB
          down-regulated_JJ by_IN Tat_NNP during_IN activation_NN of_IN the_DT latent_NN
          virus_NN [_NN 22_CD ]_NN ._. Along_IN these_DT lines_NNS ,_, a_DT Tat_NNP peptide_NN
          antagonist_NN ,_, which_WDT bound_VBN specifically_RB to_TO TAR_NNP RNA_NNP and_CC
          competed_VBN with_IN Tat_NNP for_IN binding_JJ ,_, reduced_VBD Tat-dependent_NNP
          translation_NN [_NN 42_CD ]_NN ._.
          Finally_RB ,_, upregulation_NN of_IN translation_NN genes_NNS in_IN Tat_NNP
          expressing_VBG cells_NNS is_VBZ specially_RB intriguing_JJ in_IN light_NN of_IN the_DT
          recent_JJ discovery_NN of_IN internal_JJ ribosome_NN entry_NN sites_NNS (_( IRESs_NNP )_)
          in_IN HIV-_NNP 1_CD gag_NN ORF_NNP [_NN 43_CD ]_NN ._. IRESs_NNP are_VBP thought_VBN to_TO promote_VB
          initiation_NN of_IN translation_NN by_IN directly_RB binding_JJ to_TO
          ribosomes_NNS ,_, in_IN a_DT manner_NN independent_JJ of_IN the_DT mRNA_NN cap_NN or_CC of_IN
          scanning_VBG through_IN upstream_JJ sequences_NNS ._. Since_IN ,_, the_DT TAR_NNP is_VBZ
          located_VBN at_IN the_DT 5_CD '_POS end_NN of_IN all_DT HIV-_NNP 1_CD RNA_NNP transcripts_NNS and_CC
          the_DT presence_NN of_IN secondary_JJ structure_NN at_IN or_CC near_IN the_DT 5_CD '_POS end_NN
          of_IN RNAs_NNP reduces_VBZ the_DT accessibility_NN of_IN the_DT 5_CD '_POS cap_NN to_TO eIF_NN 4_CD F_NN ,_,
          it_PRP is_VBZ thought_VBN that_IN this_DT feature_NN of_IN HIV-_NNP 1_CD mRNAs_NNS can_MD
          inhibit_VB their_PRP$ cap-dependent_JJ translation_NN [_NN 44_CD 45_CD 46_CD ]_NN ._.
          Therefore_RB ,_, a_DT possible_JJ function_NN of_IN the_DT HIV-_NNP 1_CD gag_NN IRES_NNP
          might_MD be_VB to_TO serve_VB as_IN a_DT mechanism_NN to_TO bypass_VB the_DT structural_JJ
          barriers_NNS to_TO cap-dependent_JJ translation_NN by_IN recruiting_VBG
          ribosomes_NNS easily_RB and_CC directly_RB to_TO the_DT gag_NN ORFs_NNP ._. IRES_NNP
          entirely_RB contained_VBD within_IN a_DT translated_VBN ORF_NNP has_VBZ been_VBN shown_VBN
          in_IN the_DT MMLV_NNP gag_NN [_NN 47_CD ]_NN ,_, and_CC host_NN mRNA_NN encoding_VBG p_NN 110_CD
          PITSLREand_NNP p_NN 58_CD PITSLRE_NNP [_NN 48_CD ]_NN ._. Along_IN these_DT lines_NNS ,_,
          cap-dependent_JJ translation_NN may_MD be_VB cell_NN cycle_NN regulated_VBN ,_,
          especially_RB when_WRB cells_NNS are_VBP arrested_VBN at_IN the_DT G_NNP 2_CD phase_NN of_IN the_DT
          cell_NN cycle_NN ,_, where_WRB the_DT cap-dependent_JJ translation_NN of_IN most_JJS
          cellular_JJ host_NN cell_NN mRNAs_NNS is_VBZ inhibited_VBD [_NN 49_CD 50_CD 51_CD ]_NN ._.
        
        
          Modulation_NNP of_IN signal_NN transduction_NN pathway_NN
          Results_NNS in_IN Table_NNP 3_CD indicate_VBP that_IN many_JJ seemingly_RB
          different_JJ pathways_NNS are_VBP being_VBG regulated_VBN by_IN Tat_NNP ._. However_RB ,_,
          the_DT signal_NN transduction_NN pathway_NN ,_, MAPK_NNP ,_, has_VBZ been_VBN shown_VBN to_TO
          control_VB and_CC be_VB upstream_RB of_IN DNA-replication_NNP ,_,
          transcription_NN ,_, and_CC cell_NN cycle_NN pathways_NNS [_NN 52_CD 53_CD 54_CD ]_NN ._. The_DT
          mitogen-activated_JJ protein_NN kinase_NN (_( MAPK_NNP )_) pathway_NN ,_,
          consisting_VBG of_IN the_DT MAP_NNP kinase_NN kinases_NNS (_( MKKs_NNP )_) 1_CD and_CC 2_CD ,_, and_CC
          extracellular_NN signal-regulated_JJ kinases_NNS (_( ERKs_NNP )_) 1_CD and_CC 2_CD ,_,
          which_WDT have_VBP been_VBN implicated_VBN in_IN diverse_JJ cellular_JJ processes_VBZ
          including_VBG proliferation_NN ,_, transformation_NN ,_, and_CC cell_NN
          differentiation_NN [_NN 53_CD ]_NN ._. The_DT MAP_NNP kinase_NN (_( MAPK_NNP )_) pathway_NN
          has_VBZ emerged_VBN as_IN a_DT crucial_JJ route_NN between_IN membrane-bound_JJ Ras_NNP
          and_CC the_DT nucleus_NN ._. This_DT MAPK_NNP pathway_NN encompasses_VBZ a_DT cascade_NN
          of_IN phosphorylation_NN events_NNS involving_VBG three_CD key_JJ kinases_NNS ,_,
          namely_RB Raf_NNP ,_, MEK_NNP (_( MAP_NNP kinase_NN kinase_NN )_) and_CC ERK_NNP (_( MAP_NNP kinase_NN )_) ._.
          The_DT MAPK_NNP pathway_NN controls_NNS ERKs_NNP 1_CD and_CC 2_CD ,_, c-_NN Jun_NNP N-_NNP terminal_NN
          kinase_NN (_( JNK_NNP )_) ,_, and_CC p_NN 38_CD ._. These_DT signaling_VBG pathways_NNS in_IN turn_NN ,_,
          activate_VBP a_DT variety_NN of_IN transcription_NN factors_NNS including_VBG
          NF-kappaB_NNP (_( p_NN 50_CD /_NN p_NN 65_CD )_) ,_, AP-_NNP 1_CD (_( c-_NN Fos_NNP /_NN c-_NN Jun_NNP )_) ,_, and_CC CREB_NNP
          phosphorylation_NN ,_, which_WDT in_IN turn_NN coordinate_VB the_DT induction_NN
          of_IN many_JJ genes_NNS encoding_VBG inflammatory_JJ mediators_NNS ._.
          Cytokine_NNP receptors_NNS such_JJ as_IN IL-_NNP 3_CD ,_, GM-CSF_NNP ,_, and_CC the_DT
          interferons_NNS transmit_VB their_PRP$ regulatory_JJ signals_NNS primarily_RB
          by_IN the_DT receptor-associated_JJ Jak_NNP family_NN of_IN tyrosine_NN
          kinases_NNS ,_, and_CC activate_VBP STAT_NNP transcription_NN factors_NNS ._.
          Activated_NNP STAT_NNP 5_CD proteins_NNS are_VBP detected_VBN in_IN reduced_VBN levels_NNS
          in_IN lymphocytes_NNS recovered_VBD from_IN HIV-infected_NNP patients_NNS and_CC
          immunocompromised_JJ mice_NNS ._. Both_DT of_IN these_DT types_NNS of_IN receptor_NN
          signaling_VBG pathways_NNS have_VBP recently_RB been_VBN shown_VBN to_TO interact_NN
          with_IN serine_NN /_NN threonine_NN kinases_NNS such_JJ as_IN MAP_NNP kinases_NNS ._. A_DT
          common_JJ intermediate_JJ pathway_NN initiating_VBG from_IN receptors_NNS to_TO
          the_DT nucleus_NN is_VBZ the_DT Ras_NNP /_NN Raf_NNP /_NN MEK_NNP /_NN ERK_NNP (_( MAPK_NNP )_) cascade_NN ,_, which_WDT
          can_MD result_VB in_IN the_DT phosphorylation_NN and_CC activation_NN of_IN
          additional_JJ downstream_JJ kinases_NNS and_CC transcription_NN factors_NNS
          such_JJ as_IN p_NN 90_CD Rsk_NNP ,_, CREB_NNP ,_, Elk_NNP ,_, and_CC Egr-_NNP 1_CD [_NN 55_CD 56_CD ]_NN ._.
          Therefore_RB ,_, it_PRP is_VBZ intriguing_JJ that_IN Tat_NNP expressing_VBG cells_NNS
          show_VBP down-regulation_JJ of_IN MAPK_NNP components_NNS (_( Table_NNP 3_CD ,_, Figure_NN
          3_CD Band_NNP 3_CD C_NNP )_) ,_, essential_JJ mediators_NNS between_IN receptors_NNS and_CC
          nuclear_JJ transcription_NN factors_NNS ._. This_DT would_MD imply_VB that_IN
          latently_RB infected_JJ cells_NNS that_WDT express_VBP Tat_NNP (_( doubly_RB spliced_JJ
          RNA_NNP )_) and_CC not_RB the_DT whole_JJ virus_NN (_( all_DT three_CD classes_NNS of_IN the_DT
          RNA_NNP )_) ,_, can_MD control_VB signal_NN transduction_NN related_VBN to_TO membrane_NN
          and_CC transcriptional_NN signaling_VBG (_( Figure_NN 6_CD )_) ._.
          Interestingly_RB ,_, Tat_NNP ,_, through_IN the_DT RGD_NNP motif_NN ,_, which_WDT
          controls_VBZ integrin-based_JJ cell_NN signaling_VBG ,_, has_VBZ been_VBN reported_VBN
          to_TO mediate_VB the_DT activity_NN of_IN phosphotyrosine_NN
          phosphatase_NN (_( s_VBZ )_) ._. This_DT in_IN turn_NN which_WDT would_MD lead_VB to_TO a_DT
          decrease_NN in_IN the_DT levels_NNS of_IN phosphotyrosine-containing_JJ
          proteins_NNS such_JJ as_IN ERK-_NNP 2_CD /_NN p_NN 42_CD MAPK_NNP kinases_NNS [_NN 57_CD ]_NN ._.
          Cysteine-rich_NNP and_CC basic_JJ Tat_NNP peptides_NNS have_VBP been_VBN shown_VBN to_TO
          inhibit_VB VEGF-induced_NNP ERK_NNP activation_NN and_CC mitogenesis_NNS ._.
          These_DT peptides_NNS also_RB inhibited_VBD proliferation_NN ,_,
          angiogenesis_NNS ,_, and_CC ERK_NNP activation_NN induced_VBN by_IN basic_JJ
          fibroblast_NN growth_NN factor_NN with_IN similar_JJ potency_NN and_CC
          efficacy_NN [_NN 58_CD ]_NN ._. Consistent_NNP with_IN this_DT model_NN ,_, it_PRP has_VBZ been_VBN
          shown_VBN that_DT treatment_NN of_IN neural_NN cells_NNS with_IN culture_NN
          supernatants_NNS from_IN HAART-treated_NNP subjects_NNS ,_, which_WDT
          presumably_RB contain_VB extracellular_NN Tat_NNP ,_, resulted_VBD in_IN
          down-regulation_JJ of_IN the_DT JNK_NNP ,_, AKT_NNP ,_, and_CC ERK_NNP kinases_NNS [_NN 59_CD ]_NN
          ._.
          Finally_RB ,_, activation_NN of_IN MAPKs_NNP has_VBZ been_VBN shown_VBN to_TO
          activate_VBP the_DT singly_RB spliced_JJ and_CC unspliced_JJ (_( genomic_JJ )_)
          latent_NN HIV-_NNP 1_CD virus_NN ._. For_IN instance_NN ,_, the_DT signal_NN transduction_NN
          pathways_NNS that_WDT regulate_VB the_DT switch_NN from_IN latent_NN to_TO
          productive_JJ infection_NN have_VBP been_VBN linked_VBN to_TO MAPK_NNP ._. The_DT
          induction_NN of_IN latent_NN HIV-_NNP 1_CD expression_NN has_VBZ been_VBN shown_VBN to_TO be_VB
          inhibited_VBD by_IN PD_NNP 98059_CD and_CC U_NNP 0126_CD ,_, specific_JJ inhibitors_NNS of_IN
          MAPK_NNP activation_NN ._. The_DT MAPK_NNP acts_NNS by_IN stimulating_VBG AP-_NNP 1_CD and_CC a_DT
          subsequent_JJ physical_JJ and_CC functional_JJ interaction_NN of_IN AP-_NNP 1_CD
          with_IN NF-κB_NNP ,_, resulting_VBG in_IN a_DT complex_NN that_IN synergistically_RB
          transactivates_NNS the_DT HIV-_NNP 1_CD [_NN 60_CD ]_NN ._. At_IN the_DT level_NN of_IN
          infection_NN and_CC entry_NN ,_, the_DT activation_NN of_IN MAPK_NNP through_IN the_DT
          Ras_NNP /_NN Raf_NNP /_NN MEK_NNP (_( MAPK_NNP kinase_NN )_) signaling_VBG pathway_NN enhances_VBZ the_DT
          infectivity_NN of_IN HIV-_NNP 1_CD virions_NNS ._. Virus_NNP infectivity_NN can_MD be_VB
          enhanced_VBN by_IN treatment_NN of_IN cells_NNS with_IN MAPK_NNP stimulators_NNS ,_,
          such_JJ as_IN serum_NN and_CC phorbol_NN myristate_NN acetate_NN ,_, as_RB well_RB as_IN
          by_IN coexpression_NN of_IN constitutively_RB activated_VBN Ras_NNP ,_, Raf_NNP ,_, or_CC
          MEK_NNP in_IN the_DT absence_NN of_IN extracellular_NN stimulation_NN [_NN 61_CD ]_NN ._.
          Also_RB ,_, following_VBG infection_NN ,_, efficient_JJ disengagement_NN of_IN the_DT
          reverse_JJ transcription_NN complex_JJ from_IN the_DT cell_NN membrane_NN and_CC
          subsequent_JJ nuclear_JJ translocation_NN ,_, requires_VBZ
          phosphorylation_NN of_IN the_DT reverse_JJ transcription_NN complex_JJ
          components_NNS by_IN ERK_NNP /_NN MAPK_NNP ;_: demonstrating_VBG a_DT critical_JJ
          regulation_NN of_IN an_DT early_JJ step_NN in_IN HIV-_NNP 1_CD infection_NN by_IN the_DT
          host_NN cell_NN MAPK_NNP signal_NN transduction_NN pathway_NN [_NN 62_CD ]_NN ._.
          Therefore_RB ,_, Tat_NNP down-regulation_JJ of_IN the_DT MAPK_NNP pathway_NN in_IN
          latent_NN cells_NNS implies_VBZ that_IN much_JJ of_IN the_DT host_NN signal_NN
          transductions_NNS connected_VBN to_TO activation_NN are_VBP down-regulated_JJ ,_,
          and_CC at_IN the_DT same_JJ time_NN ,_, these_DT cells_NNS may_MD be_VB refractory_JJ to_TO
          subsequent_JJ infection_NN by_IN other_JJ viruses_NNS ._.
        
        
          Thymosin_NNP family_NN members_NNS ,_, and_CC cell_NN cycle_NN
          Prothymosin_NNP α_NN (_( ProTα_NNP )_) belongs_VBZ to_TO the_DT α-_NN Thymosin_NNP family_NN
          which_WDT comprises_VBZ different_JJ polypeptides_NNS widely_RB distributed_VBN
          within_IN animal_NN tissues_NNS ._. Although_IN its_PRP$ role_NN has_VBZ remained_VBN
          controversial_JJ ,_, it_PRP is_VBZ involved_VBN in_IN the_DT increase_NN of_IN
          immediate_JJ early_JJ genes_NNS such_JJ as_IN c-myc_JJ [_NN 63_CD ]_NN ,_, which_WDT is_VBZ
          upstream_RB of_IN cyclin_NN D_NNP synthesis_NN and_CC necessary_JJ for_IN cell_NN
          division_NN [_NN 64_CD ]_NN ._. In_IN humans_NNS ,_, ProTα_NNP is_VBZ coded_VBN by_IN a_DT gene_NN
          family_NN of_IN six_CD members_NNS ._. One_CD of_IN them_PRP contains_VBZ introns_NNS ,_,
          exons_NNS and_CC classic_JJ regulatory_JJ signals_NNS ,_, while_IN the_DT remaining_VBG
          five_CD are_VBP intronless_JJ genes_NNS [_NN 59_CD ]_NN located_VBN on_IN chromosome_NN 2_CD
          [_NN 66_CD ]_NN ._. There_EX are_VBP two_CD mRNA_NN transcripts_NNS ,_, which_WDT arise_VBP in_IN a_DT
          ratio_NN of_IN 9_CD :_: 1_CD (_( shorter_JJR /_NN longer_JJR form_NN )_) ,_, where_WRB only_RB the_DT long_JJ
          transcript_NN is_VBZ regulated_VBN by_IN extracellular_NN signals_NNS ._.
          It_PRP has_VBZ been_VBN demonstrated_VBN that_IN malignant_JJ tissues_NNS with_IN
          accelerated_JJ cell_NN cycle_NN show_NN higher_JJR levels_NNS of_IN ProTα_NNP
          expression_NN than_IN normal_JJ or_CC surrounding_VBG healthy_JJ tissues_NNS [_NN
          67_CD ]_NN ._. ProTα_NNP was_VBD shown_VBN as_IN a_DT marker_NN for_IN breast_NN cancer_NN [_NN 68_CD
          ]_NN ,_, hepatocarcinoma_NN [_NN 69_CD ]_NN ,_, and_CC plasma_NN levels_NNS of_IN its_PRP$
          derivative_JJ Tα_NNP 
          1_CD been_VBN proposed_VBN as_IN a_DT marker_NN for_IN the_DT
          prognosis_NN of_IN lung_NN cancer_NN [_NN 70_CD ]_NN ._. In_IN ligand_NN blotting_VBG
          assays_NNS ,_, ProTα_NNP bound_VBN only_RB to_TO chromatin_NN pools_NNS and_CC nuclear_JJ
          fractions_NNS where_WRB histone_NN H_NNP 1_CD was_VBD present_JJ [_NN 71_CD 72_CD ]_NN ._. The_DT
          analysis_NN of_IN the_DT interaction_NN of_IN ProTα_NNP with_IN H_NNP 1_CD -_: containing_VBG
          chromatin_NN suggests_VBZ a_DT putative_JJ role_NN for_IN ProTα_NNP in_IN the_DT
          fine-tuning_NN of_IN the_DT stoichiometry_NN and_CC /_NN or_CC mode_NN of_IN
          interaction_NN of_IN H_NNP 1_CD with_IN chromatin_NN [_NN 73_CD ]_NN ._. Interestingly_RB ,_,
          HL-_NNP 60_CD cells_NNS overexpressing_VBG ProTα_NNP show_NN an_DT enhancement_NN of_IN
          accessibility_NN of_IN micrococcal_NN nuclease_NN to_TO chromatin_NN ,_,
          implying_VBG relaxed_VBN chromatin_NN structure_NN for_IN enhanced_JJ cell_NN
          cycle_NN gene_NN expression_NN [_NN 74_CD ]_NN ._.
          A_DT broad_JJ study_NN using_VBG several_JJ mononuclear_NN and_CC
          fibroblastic_JJ cell_NN lines_NNS has_VBZ shown_VBN that_IN ProTα_NNP mRNA_NN
          accumulation_NN is_VBZ cell_NN cycle_NN phase-dependent_JJ ._. In_IN the_DT U_NNP 937_CD
          monocytic_JJ cell_NN line_NN ,_, ProTα_NNP mRNA_NN peaked_VBD at_IN the_DT end_NN of_IN S_NNP /_NN G_NNP 2_CD
          phase_NN and_CC fell_VBD towards_IN the_DT entry_NN into_IN the_DT new_JJ G_NNP 1_CD phase_NN ._.
          More_RBR prominent_JJ mRNA_NN regulation_NN was_VBD found_VBN in_IN the_DT
          fibroblastic_JJ cell_NN lines_NNS CV_NNP 1_CD and_CC NIH_NNP 3_CD T_NN 3_CD ,_, with_IN peak_NN mRNA_NN
          levels_NNS at_IN the_DT end_NN of_IN S-_NNP phase_NN ._. In_IN all_DT cases_VBZ the_DT expression_NN
          pattern_NN coincided_VBD with_IN that_DT of_IN cyclin_NN B_NNP and_CC Cdc_NNP 2_CD /_NN cyclin_NN B_NNP
          activation_NN [_NN 75_CD ]_NN ._.
          It_PRP is_VBZ interesting_JJ to_TO note_VB that_IN Cdc_NNP 2_CD (_( Acc_NNP #_# X_NNP 05360_CD )_) ,_,
          Cdc_NNP 10_CD homolog_NN (_( Acc_NNP #_# S_NNP 72008_CD )_) ,_, and_CC Cdc_NNP 37_CD (_( Acc_NNP #_# U_NNP 43077_CD )_) were_VBD
          all_DT up-regulated_JJ in_IN Tat_NNP expressing_VBG cells_NNS ._. Cdc_NNP 2_CD ,_, a_DT
          catalytic_JJ subunit_NN of_IN cyclin-dependent_JJ kinases_NNS ,_, is_VBZ
          required_VBN for_IN both_DT the_DT G_NNP 1_CD -_: to-_NN S_NNP and_CC G_NNP 2_CD -_: to-_NN M_NNP transitions_NNS ._. In_IN
          the_DT fission_NN yeast_NN Schizosaccharomyces_NNP pombe_NN ,_, the_DT
          execution_NN of_IN Start_NNP requires_VBZ the_DT activity_NN of_IN the_DT Cdc_NNP 2_CD
          protein_NN kinase_NN and_CC the_DT Cdc_NNP 10_CD /_NN Sct_NNP 1_CD transcription_NN complex_JJ ._.
          The_DT loss_NN of_IN any_DT of_IN these_DT genes_NNS leads_VBZ to_TO G_NNP 1_CD arrest_NN [_NN 69_CD ]_NN
          ._.
          Cdc_NNP 37_CD encodes_NNS a_DT 50_CD -_: kDa_NN protein_NN that_IN targets_NNS
          intrinsically_RB unstable_JJ oncoprotein_NN kinases_NNS including_VBG
          Cdk_NNP 4_CD ,_, Raf-_NNP 1_CD ,_, and_CC v-src_JJ to_TO the_DT molecular_JJ chaperone_NN Hsp_NNP 90_CD ,_,
          an_DT interaction_NN that_WDT is_VBZ thought_VBN to_TO be_VB important_JJ for_IN the_DT
          establishment_NN of_IN signaling_VBG pathways_NNS ._. Cdc_NNP 37_CD expression_NN may_MD
          not_RB only_RB be_VB required_VBN to_TO support_VB proliferation_NN in_IN cells_NNS
          that_WDT are_VBP developmentally_RB programmed_VBN to_TO proliferate_VBP ,_, but_CC
          may_MD also_RB be_VB required_VBN in_IN cells_NNS that_WDT are_VBP inappropriately_RB
          induced_VBN to_TO initiate_VB proliferation_NN by_IN oncogenes_NNS ._. For_IN
          instance_NN ,_, MMTV-Cdc_NNP 37_CD transgenic_JJ mice_NNS develop_VBP mammary_JJ
          gland_NN tumors_NNS at_IN a_DT rate_NN comparable_JJ to_TO that_DT observed_VBD
          previously_RB in_IN MMTV-cyclin_NNP D_NNP 1_CD mice_NNS ,_, indicating_VBG that_IN Cdc_NNP 37_CD
          can_MD function_VB as_IN an_DT oncogene_NN in_IN mice_NNS and_CC suggests_VBZ that_IN the_DT
          establishment_NN of_IN protein_NN kinase_NN pathways_NNS mediated_JJ by_IN
          Cdc_NNP 37_CD -_: Hsp_NNP 90_CD can_MD be_VB a_DT rate-limiting_JJ event_NN in_IN
          transformation_NN [_NN 76_CD ]_NN ._. Also_RB ,_, analysis_NN of_IN proteins_NNS that_IN
          co-immunoprecipitated_JJ with_IN Cdk_NNP 6_CD and_CC Cdk_NNP 4_CD has_VBZ shown_VBN
          complexes_NNS containing_VBG both_DT Hsp_NNP 90_CD and_CC Cdc_NNP 37_CD [_NN 77_CD 78_CD 79_CD ]_NN
          ._.
          Cdc_NNP 37_CD also_RB promotes_VBZ the_DT production_NN of_IN Cak_NNP 1_CD ._. Cak_NNP 1_CD in_IN
          yeast_NN is_VBZ the_DT human_JJ homolog_NN of_IN CAK_NNP trimeric_JJ enzyme_NN
          containing_VBG CDK_NNP 7_CD ,_, cyclin_NN H_NNP ,_, and_CC MAT_NNP 1_CD ._. Both_DT human_NN and_CC yeast_NN
          Caks_NNP function_NN as_IN RNA_NNP polymerase_NN II_NNP CTD_NNP kinase_NN ,_, Cdk_NNP
          activating_VBG kinase_NN ,_, and_CC DNA_NNP damage_NN /_NN repair_NN enzymes_NNS ._. Cdc_NNP 37_CD ,_,
          like_IN its_PRP$ higher_JJR eukaryotic_JJ homologs_NNS ,_, promotes_VBZ the_DT
          physical_JJ integrity_NN of_IN multiple_JJ protein_NN kinases_NNS ,_, perhaps_RB
          by_IN virtue_NN of_IN a_DT cotranslational_NN role_NN in_IN protein_NN folding_VBG [_NN
          80_CD ]_NN ._. Finally_RB ,_, Hsp_NNP 90_CD /_NN Cdc_NNP 37_CD has_VBZ recently_RB been_VBN shown_VBN in_IN
          the_DT stabilization_NN /_NN folding_NN of_IN Cdk_NNP 9_CD as_RB well_RB as_IN the_DT assembly_NN
          of_IN an_DT active_JJ Cdk_NNP 9_CD /_NN cyclin_NN T_NN 1_CD complex_JJ responsible_JJ for_IN
          P-TEF_NNP b-mediated_JJ Tat_NNP transactivation_NN [_NN 81_CD ]_NN ._.
        
        
          Transcription_NNP and_CC chromatin_NN remodeling_VBG
          factors_NNS
          A_DT highly_RB ordered_VBN chromatin_NN structure_NN presents_VBZ a_DT
          physical_JJ obstacle_NN for_IN gene_NN transcription_NN ;_: presumably_RB by_IN
          limiting_VBG the_DT access_NN of_IN transcription_NN factors_NNS and_CC RNA_NNP
          polymerase_NN II_NNP core_NN machinery_NN to_TO target_VB DNA_NNP [_NN 82_CD 83_CD ]_NN ._. In_IN
          concert_NN with_IN the_DT observation_NN that_IN corepressors_NNS are_VBP
          associated_VBN with_IN HDAC_NNP activities_NNS [_NN 84_CD 85_CD ]_NN ,_, it_PRP appears_VBZ
          that_IN the_DT transcriptional_NN outcome_NN of_IN nuclear_JJ receptors_NNS is_VBZ
          determined_VBN by_IN the_DT balance_NN of_IN histone_NN acetylation_NN and_CC
          deacetylation_NN activities_NNS ,_, and_CC that_IN ligands_NNS serve_VBP as_IN a_DT
          switch_NN to_TO recruit_VB HATs_NNP with_IN the_DT concomitant_NN dismissal_NN of_IN
          HDACs_NNP ._. Signal_NNP transduction_NN pathways_NNS add_VBP another_DT layer_NN of_IN
          regulation_NN to_TO the_DT functions_NNS of_IN CBP_NNP /_NN p_NN 300_CD ._. In_IN the_DT case_NN of_IN
          the_DT POU_NNP homeodomain_NN factor_NN Pit-_NNP 1_CD ,_, transcriptional_NN
          activity_NN is_VBZ potentiated_JJ by_IN MAPK_NNP pathways_NNS [_NN 86_CD ]_NN ._.
          Therefore_RB ,_, down-regulation_JJ of_IN MAPK_NNP pathway_NN members_NNS in_IN Tat_NNP
          expressing_VBG cells_NNS ,_, as_IN seen_VBN in_IN Table_NNP 3_CD ,_, is_VBZ consistent_JJ with_IN
          decreased_VBD phosphorylation_NN of_IN DNA_NNP binding_JJ factors_NNS such_JJ as_IN
          Pit-_NNP 1_CD ,_, and_CC overall_JJ lower_JJR DNA_NNP binding_JJ activity_NN ._. Here_RB ,_, we_PRP
          describe_VBP the_DT effect_NN of_IN coactivator_NN proteins_NNS SRC-_NNP 1_CD (_( Acc_NNP #_#
          AJ_NNP 000882_CD ,_, U_NNP 90661_CD ,_, Table_NNP 1_LS )_) and_CC p_NN 300_CD (_( Acc_NNP #_# U_NNP 01877_CD ,_, Table_NNP
          3_LS )_) ,_, and_CC their_PRP$ relation_NN to_TO differentiation_NN genes_NNS such_JJ as_IN
          retinoic_JJ acid_NN receptor_NN (_( RAR_NNP /_NN PML_NNP ,_, Acc_NNP #_# :_: X_NNP 06614_CD ,_, Table_NNP 1_LS )_) ,_,
          and_CC Leptin_NNP receptor_NN variant_NN (_( Acc_NNP #_# :_: U_NNP 66496_CD ,_, Table_NNP 1_LS )_) ;_: all_DT
          of_IN which_WDT are_VBP down-regulated_JJ in_IN Tat_NNP expressing_VBG cells_NNS
          (_( Figure_NN 5_LS )_) ._.
          Over_IN the_DT past_JJ three_CD decades_NNS a_DT great_JJ deal_NN of_IN evidence_NN
          has_VBZ accumulated_VBN in_IN favor_NN of_IN the_DT hypothesis_NNS that_WDT steroid_NN
          receptor_NN hormones_NNS act_VBP via_IN regulation_NN of_IN gene_NN expression_NN ._.
          The_DT action_NN is_VBZ mediated_JJ by_IN specific_JJ nuclear_JJ receptor_NN
          proteins_NNS ,_, which_WDT belong_VBP to_TO a_DT superfamily_RB of_IN
          ligand-modulated_JJ transcription_NN factors_NNS that_WDT regulate_VB
          homeostasis_NNS ,_, reproduction_NN ,_, development_NN ,_, and_CC
          differentiation_NN [_NN 87_CD ]_NN ._. This_DT family_NN includes_VBZ receptors_NNS
          for_IN steroid_NN hormones_NNS ,_, thyroid_NN hormones_NNS ,_, hormonal_NN forms_NNS of_IN
          vitamin_NN A_DT and_CC D_NNP ,_, peroxisomal_NN activators_NNS ,_, and_CC ecdysone_NN [_NN
          88_CD ]_NN ._. Nuclear_NNP hormone_NN receptors_NNS are_VBP ligand-dependent_JJ
          transcription_NN factors_NNS that_WDT regulate_VB genes_NNS critical_JJ to_TO
          such_JJ biological_JJ processes_NNS as_IN development_NN ,_, reproduction_NN ,_,
          and_CC homeostasis_NNS ._. Interestingly_RB ,_, these_DT receptors_NNS can_MD
          function_VB as_IN molecular_JJ switches_NNS ,_, alternating_VBG between_IN
          states_NNS of_IN transcriptional_NN repression_NN and_CC activation_NN ,_,
          depending_VBG on_IN the_DT absence_NN or_CC presence_NN of_IN a_DT cognate_NN
          hormone_NN ,_, respectively_RB ._. In_IN the_DT absence_NN of_IN cognate_NN hormone_NN ,_,
          several_JJ nuclear_JJ receptors_NNS actively_RB repress_NNS transcription_NN
          of_IN target_NN genes_NNS via_IN interactions_NNS with_IN the_DT nuclear_JJ
          receptor_NN corepressors_NNS SMRT_NNP and_CC NCoR_NNP ._. Upon_IN binding_VBG of_IN the_DT
          hormone_NN ,_, these_DT corepressors_NNS dissociate_VB from_IN the_DT DNA-bound_NNP
          receptor_NN ,_, which_WDT subsequently_RB recruits_VBZ a_DT nuclear_JJ receptor_NN
          coactivator_NN (_( NCoA_NNP )_) complex_JJ ._. Prominent_NNP among_IN these_DT
          coactivators_NNS is_VBZ the_DT SRC_NNP (_( steroid_NN receptor_NN coactivator_NN )_)
          family_NN ,_, which_WDT consists_VBZ of_IN SRC-_NNP 1_CD ,_, TIF_NNP 2_CD /_NN GRIP_NNP 1_CD ,_, and_CC
          RAC_NNP 3_CD /_NN ACTR_NNP /_NN pCIP_NN /_NN AIB-_NNP 1_CD ._. These_DT cofactors_NNS interact_NN with_IN
          nuclear_JJ receptors_NNS in_IN a_DT ligand-dependent_JJ manner_NN and_CC
          enhance_VB transcriptional_NN activation_NN via_IN histone_NN
          acetylation_NN /_NN methylation_NN and_CC recruitment_NN of_IN additional_JJ
          cofactors_NNS such_JJ as_IN CBP_NNP /_NN p_NN 300_CD [_NN 89_CD ]_NN ._. CBP_NNP /_NN p_NN 300_CD has_VBZ been_VBN
          implicated_VBN in_IN the_DT functions_NNS of_IN a_DT large_JJ number_NN of_IN
          regulated_VBN transcription_NN factors_NNS based_VBN primarily_RB on_IN
          physical_JJ interaction_NN and_CC the_DT ability_NN to_TO potentiate_NN
          transcription_NN when_WRB overexpressed_JJ [_NN 90_CD ]_NN ._. In_IN the_DT case_NN of_IN
          nuclear_JJ receptors_NNS ,_, the_DT interaction_NN with_IN CBP_NNP /_NN p_NN 300_CD is_VBZ
          ligand-dependent_JJ and_CC relies_VBZ on_IN the_DT conserved_JJ nuclear_JJ
          receptor_NN functional_JJ domain_NN ,_, AF-_NNP 2_CD (_( activation_NN function_NN 2_LS )_) ._.
          
          In_IN vivo_NN studies_NNS have_VBP supported_VBN the_DT
          conclusion_NN that_IN CBP_NNP /_NN p_NN 300_CD are_VBP components_NNS of_IN the_DT
          hormonal-regulation_JJ of_IN transcription_NN in_IN fibroblasts_NNS
          isolated_VBN from_IN a_DT p_NN 300_CD -_: /_NN -_: mouse_NN ;_: and_CC loss_NN of_IN the_DT p_NN 300_CD gene_NN
          severely_RB affects_VBZ retinoic_JJ acid_NN (_( RA_NNP )_) -_: dependent_JJ
          transcription_NN [_NN 91_CD ]_NN ._. In_IN a_DT separate_JJ study_NN using_VBG
          hammerhead_NN ribozymes_NNS that_WDT specifically_RB cleave_NN CBP_NNP or_CC p_NN 300_CD
          mRNA_NN ,_, Kawasaki_NNP et_CC al_NN [_NN 92_CD ]_NN reported_VBD that_WDT reduced_VBD
          cellular_JJ CBP_NNP or_CC p_NN 300_CD levels_NNS resulted_VBD in_IN compromised_VBN
          expression_NN of_IN endogenous_JJ RA-inducible_NNP genes_NNS such_JJ as_IN
          p_NN 21_CD /_NN Waf_NNP 1_CD and_CC p_NN 27_CD cdk_NN inhibitors_NNS ._. Along_IN this_DT line_NN ,_, Tat_NNP
          expressing_VBG cells_NNS have_VBP lower_JJR levels_NNS of_IN p_NN 21_CD /_NN Waf_NNP 1_CD presumably_RB
          due_JJ to_TO inactivation_NN of_IN p_NN 53_CD and_CC a_DT lack_NN of_IN p_NN 300_CD /_NN RA-_NNP induced_VBD
          gene_NN expression_NN ._. Consistent_NNP with_IN this_DT interpretation_NN ,_, CBP_NNP
          and_CC p_NN 300_CD harbor_NN transcriptional_NN activation_NN of_IN
          ligand-induced_JJ RA_NNP or_CC ER_NNP function_NN on_IN a_DT chromatinized_JJ
          template_NN [_NN 93_CD ]_NN ._.
          The_DT NcoA_NNP family_NN members_NNS constitute_VBP SRC-_NNP 1_CD /_NN NcoA-_NNP 1_CD [_NN 89_CD ]_NN
          ,_, TIF_NNP 2_CD /_NN GRIP_NNP 1_CD /_NN NcoA-_NNP 2_CD ,_, [_NN 94_CD 95_CD ]_NN and_CC pCIP_NN /_NN ACTR_NNP /_NN AIB_NNP 1_CD [_NN 96_CD 97_CD
          98_CD ]_NN proteins_NNS ,_, which_WDT interact_NN with_IN liganded_JJ RA_NNP receptor_NN
          (_( RAR_NNP )_) ,_, and_CC CBP_NNP /_NN p_NN 300_CD ._. Overexpression_NNP of_IN these_DT NCoA_NNP factors_NNS
          enhances_VBZ ligand-induced_JJ transactivation_NN of_IN several_JJ
          nuclear_JJ receptors_NNS [_NN 99_CD ]_NN ._. A_DT weak_JJ intrinsic_JJ HAT_NNP activity_NN
          has_VBZ been_VBN reported_VBN in_IN SRC-_NNP 1_CD /_NN NCoA-_NNP 1_CD and_CC pCIP_NN /_NN ACTR_NNP /_NN AIB_NNP 1_CD ,_,
          suggesting_VBG that_DT chromatin_NN remodeling_VBG may_MD also_RB be_VB a_DT
          function_NN of_IN these_DT NCoA_NNP factors_NNS [_NN 99_CD 100_CD ]_NN ;_: although_IN they_PRP
          do_VBP not_RB appear_VB to_TO contain_VB regions_NNS homologous_RB to_TO the_DT HAT_NNP
          domains_NNS of_IN CBP_NNP /_NN p_NN 300_CD or_CC p_NN /_NN CAF_NNP ._. Structure-function_NNP analysis_NN
          of_IN the_DT NCoAs_NNP have_VBP revealed_VBN multiple_JJ copies_NNS of_IN a_DT signature_NN
          motif_NN ,_, LXXLL_NNP ,_, with_IN conserved_JJ spacing_VBG that_WDT is_VBZ required_VBN for_IN
          interaction_NN with_IN nuclear_JJ receptors_NNS and_CC CBP_NNP /_NN p_NN 300_CD [_NN 99_CD 101_CD
          ]_NN ._. Intriguingly_NNP ,_, different_JJ LXXLL_NNP motifs_NNS are_VBP required_VBN for_IN
          PPARγ_NNP (_( Peroxisome_NNP Proliferator_NNP activated_VBN receptor_NN γ_NN ,_, a_DT
          gene_NN down-regulated_JJ in_IN Tat_NNP expressing_VBG cells_NNS ;_: Acc_NNP #_# L_NNP 07592_CD ,_,
          Table_NNP 1_LS )_) function_NN in_IN response_NN to_TO different_JJ classes_NNS of_IN
          ligands_NNS ,_, suggesting_VBG distinct_JJ configuration_NN of_IN assembled_VBN
          complexes_NNS ._.
          Taken_VBN together_RB ,_, through_IN the_DT use_NN of_IN microarray_NN
          technology_NN ,_, we_PRP have_VBP described_VBN one_CD of_IN the_DT first_JJ
          observations_NNS about_IN how_WRB Tat_NNP is_VBZ able_JJ to_TO control_VB various_JJ
          host_NN cellular_JJ machineries_NNS ._. Although_IN our_PRP$ data_NNS is_VBZ
          consistent_JJ with_IN most_JJS of_IN the_DT cited_VBN literature_NN on_IN the_DT
          effects_NNS of_IN Tat_NNP in_IN infected_JJ host_NN and_CC uninfected_JJ bystander_NN
          cells_NNS ,_, we_PRP caution_VBP that_IN the_DT transcriptional_NN profiling_VBG in_IN
          chronically_RB infected_JJ cells_NNS such_JJ as_IN ACH_NNP 2_CD or_CC H_NNP 9_CD /_NN Tat_NNP cells_NNS
          may_MD not_RB necessarily_RB be_VB representative_NN of_IN the_DT pattern_NN of_IN
          expression_NN observed_VBD in_IN most_JJS cells_NNS infected_VBN by_IN other_JJ group_NN
          M_NNP ,_, N_NNP ,_, or_CC O_NNP HIV-_NNP 1_CD isolates_VBZ ._.
          We_PRP recently_RB extended_VBD our_PRP$ observations_NNS by_IN utilizing_VBG
          other_JJ HIV-_NNP 1_CD infected_JJ cells_NNS which_WDT normally_RB express_VB Tat_NNP
          (_( U_NNP 1_LS )_) ,_, and_CC addition_NN of_IN exogenous_JJ purified_JJ Tat_NNP to_TO
          uninfected_JJ PBMCs_NNP ._. Preliminary_JJ results_NNS using_VBG western_JJ blots_NNS
          supports_VBZ the_DT idea_NN that_IN genes_NNS which_WDT were_VBD altered_VBN in_IN H_NNP 9_CD /_NN Tat_NNP
          system_NN also_RB showed_VBD a_DT similar_JJ level_NN of_IN change_NN in_IN few_JJ of_IN
          the_DT tested_VBN genes_NNS (_( Figure_NN 3_CD C_NNP )_) ._. This_DT notion_NN of_IN consistency_NN
          was_VBD further_RBR confirmed_VBD using_VBG the_DT IL-_NNP 8_CD activation_NN by_IN Tat_NNP ._.
          Interleukin-_NNP 8_CD (_( IL-_NNP 8_CD )_) belongs_VBZ to_TO the_DT CXC_NNP chemokine_NN family_NN
          and_CC is_VBZ secreted_JJ by_IN several_JJ different_JJ cell_NN types_NNS ,_,
          including_VBG monocytes_NNS ,_, neutrophils_NNS ,_, endothelial_NN cells_NNS ,_,
          fibroblasts_NNS ,_, and_CC T_NN lymphocytes_NNS ._. IL-_NNP 8_CD production_NN (_( induced_VBN
          by_IN several_JJ stimuli_NNS ,_, including_VBG IL-_NNP 1_CD ,_, TNF-_NNP ,_, and_CC phorbol_NN
          myristate_NN acetate_NN )_) is_VBZ primarily_RB regulated_VBN at_IN the_DT
          transcriptional_NN level_NN ._. IL-_NNP 8_CD is_VBZ a_DT potent_JJ chemotactic_JJ
          factor_NN for_IN granulocytes_NNS and_CC T_NN lymphocytes_NNS ,_, and_CC is_VBZ found_VBN
          in_IN HIV-infected_NNP individuals_NNS ._. The_DT CXC_NNP chemokine_NN IL-_NNP 8_CD does_VBZ
          not_RB bind_NN to_TO CCR_NNP 5_CD ._. It_PRP has_VBZ previously_RB been_VBN shown_VBN that_IN IL-_NNP 8_CD
          mRNA_NN induction_NN was_VBD seen_VBN less_RBR then_RB 1_CD h_NN after_IN Tat_NNP (_( 72_CD aa_NN )_)
          stimulation_NN ,_, and_CC levels_NNS remained_VBD elevated_VBD for_IN up_IN to_TO 24_CD h_NN ,_,
          leading_VBG to_TO IL-_NNP 8_CD protein_NN production_NN [_NN 102_CD ]_NN ._. Along_IN these_DT
          lines_NNS ,_, we_PRP have_VBP previously_RB shown_VBN that_IN the_DT IL-_NNP 8_CD gene_NN is_VBZ
          expressed_VBN in_IN a_DT cell_NN cycle-dependent_JJ manner_NN in_IN cells_NNS that_WDT
          express_VBP the_DT Tat_NNP protein_NN ,_, and_CC the_DT induction_NN is_VBZ during_IN the_DT
          S_NNP phase_NN of_IN the_DT cell_NN cycle_NN and_CC regulated_VBN by_IN stable_JJ NF-kB_NNP
          binding_VBG to_TO the_DT IL-_NNP 8_CD promoter_NN [_NN 103_CD ]_NN ._. When_WRB looking_VBG for_IN
          IL-_NNP 8_CD at_IN the_DT G_NNP 1_CD /_NN S_NNP border_NN ,_, we_PRP found_VBD that_IN all_DT Tat_NNP containing_VBG
          cells_NNS ,_, including_VBG PBMCs_NNP that_WDT were_VBD treated_VBN with_IN exogenous_JJ
          Tat_NNP showed_VBD an_DT up-regulation_JJ of_IN IL-_NNP 8_CD in_IN the_DT supernatant_NN
          (_( Figure_NN 4_LS )_) ,_, further_JJ implying_VBG that_IN results_NNS obtained_VBN from_IN
          the_DT H_NNP 9_CD /_NN Tat_NNP system_NN may_MD infact_NN be_VB of_IN general_JJ physiological_JJ
          relevance_NN in_IN vivo_NN ._.
          Finally_RB ,_, throughout_IN the_DT current_JJ study_NN we_PRP came_VBD across_IN
          some_DT technical_JJ findings_NNS that_WDT were_VBD critical_JJ in_IN the_DT
          confirmation_NN of_IN most_JJS of_IN our_PRP$ results_NNS ._. For_IN instance_NN ,_, few_JJ
          genes_NNS did_VBD not_RB correlate_VBP in_IN their_PRP$ activation_NN or_CC
          suppression_NN levels_NNS when_WRB comparing_VBG fold_VB changes_NNS between_IN
          microarrays_NNS and_CC protein_NN levels_NNS using_VBG western_JJ blot_NN
          analysis_NN ._. We_PRP suspect_VBP this_DT is_VBZ because_IN many_JJ genes_NNS that_WDT are_VBP
          transcribed_JJ may_MD not_RB necessarily_RB be_VB translated_VBN ,_, due_JJ to_TO
          their_PRP$ cell_NN cycle_NN stage_NN ,_, 5_CD '_POS stem_NN and_CC loop_NN RNA_NNP structures_NNS ,_,
          varying_VBG half-lives_JJ of_IN proteins_NNS and_CC mRNAs_NNS ,_, and_CC a_DT host_NN of_IN
          other_JJ unknown_JJ variables_NNS ._. Also_RB ,_, specific_JJ changes_NNS that_WDT
          occur_VBP in_IN a_DT cell_NN may_MD not_RB be_VB required_VBN in_IN redundant_JJ pathways_NNS
          that_WDT score_NN for_IN a_DT specific_JJ function_NN ._. This_DT is_VBZ commonly_RB seen_VBN
          in_IN the_DT differences_NNS between_IN HIV-_NNP 1_CD infected_JJ or_CC Tat_NNP
          expressing_VBG 
          in_IN vitro_NN cell_NN lines_NNS and_CC AIDS_NNP
          patients_NNS PBMC_NNP samples_NNS ._. Therefore_RB ,_, other_JJ microarrays_NNS would_MD
          have_VB to_TO be_VB performed_VBN on_IN purified_JJ infected_JJ PBMCs_NNP to_TO
          confirm_VB most_JJS of_IN the_DT changes_NNS observed_VBD in_IN Tables_NNP 1_CD ,_, 2_CD ,_, and_CC
          3_CD ._. Unfortunately_RB ,_, to_TO date_NN this_DT particular_JJ issue_NN is_VBZ not_RB
          feasibly_RB addressable_JJ ,_, since_IN it_PRP is_VBZ not_RB possible_JJ to_TO isolate_VB
          a_DT homogenous_JJ population_NN of_IN infected_JJ T-_NNP or_CC Monocytic_NNP cells_NNS
          from_IN AIDS_NNP patients_NNS ._. Also_RB ,_, confirmatory_NN tests_NNS for_IN protein_NN
          expression_NN would_MD have_VB to_TO be_VB done_VBN with_IN both_DT hydrophilic_JJ
          and_CC hydrophobic_JJ extraction_NN buffers_NNS ._. For_IN instance_NN ,_, we_PRP have_VBP
          observed_VBN that_IN PCNA_NNP protein_NN ,_, which_WDT is_VBZ up-regulated_JJ in_IN Tat_NNP
          expressing_VBG cells_NNS ,_, extract_VB best_JJS with_IN hydrophobic_JJ buffers_NNS
          from_IN the_DT nucleus_NN ,_, presumably_RB due_JJ to_TO its_PRP$ binding_JJ to_TO DNA_NNP
          replication_NN machinery_NN (_( data_NNS not_RB shown_VBN )_) ._. Future_JJ
          experiments_NNS will_MD address_VB issues_NNS related_VBN to_TO differences_NNS
          between_IN various_JJ HIV-_NNP 1_CD Tat_NNP clades_NNS ,_, host_NN expression_NN levels_NNS
          between_IN T-_NNP and_CC Monocytic_NNP cells_NNS ,_, and_CC its_PRP$ effect_NN at_IN various_JJ
          stages_NNS of_IN the_DT cell_NN cycle_NN ._.
        
      
      
        Conclusions_NNP
        Expression_NNP profiling_VBG from_IN HIV-_NNP 1_CD or_CC Tat_NNP expressing_VBG cells_NNS
        holds_VBZ great_JJ promise_NN for_IN rapid_JJ functional_JJ analysis_NN ._. Here_RB ,_, we_PRP
        have_VBP described_VBN the_DT effect_NN of_IN Tat_NNP and_CC its_PRP$ alterations_NNS with_IN
        the_DT host_NN cellular_JJ gene_NN expression_NN ._. We_PRP observed_VBD that_IN more_JJR
        than_IN 2_CD /_NN 3_CD of_IN the_DT cellular_JJ genes_NNS tested_VBN were_VBD down-regulated_JJ
        by_IN Tat_NNP ._. These_DT genes_NNS belong_VBP to_TO receptor_NN ,_, co-receptor_JJ ,_, and_CC
        co-activator_JJ pathways_NNS that_WDT are_VBP part_NN of_IN serine_NN /_NN threonine_NN
        receptor_NN tyrosine_NN kinase_NN ,_, Ras_NNP /_NN Raf_NNP /_NN MEK_NNP /_NN ERK_NNP (_( MAPK_NNP )_) cascade_NN ,_,
        which_WDT control_VBP proliferative_JJ and_CC /_NN or_CC differentiation_NN signals_NNS ._.
        We_PRP also_RB observed_VBD a_DT great_JJ deal_NN of_IN increase_NN in_IN the_DT host_NN cell_NN
        translation_NN apparatus_NN with_IN the_DT possible_JJ aim_NN of_IN optimizing_VBG
        viral_JJ mRNA_NN translation_NN prior_RB to_TO viral_JJ maturation_NN and_CC
        release_NN ._. Therefore_RB ,_, HIV-_NNP 1_CD accessory_JJ doubly_RB spliced_JJ messages_NNS
        such_JJ as_IN Tat_NNP ,_, may_MD control_VB the_DT host_NN gene_NN expression_NN in_IN
        latently_RB infected_JJ cells_NNS ,_, and_CC determine_VB not_RB only_RB viral_JJ
        transcription_NN ,_, but_CC also_RB the_DT fate_NN of_IN post-transcriptional_JJ
        events_NNS ._.
      
      
        Materials_NNS and_CC method_NN
        
          Cell_NNP culture_NN
          ACH_NNP 
          2_CD cells_NNS are_VBP HIV-_NNP 1_CD infected_JJ CD_NNP 4_CD
          lymphocytic_JJ cells_NNS ,_, with_IN an_DT integrated_VBN wild-type_JJ
          single-copy_JJ chromatinized_JJ DNA_NNP ._. The_DT CEM_NNP T_NN cell_NN (_( 12_CD D_NNP 7_CD )_) is_VBZ
          the_DT parental_JJ cell_NN for_IN ACH_NNP 
          2_CD cells_NNS ._. ACH_NNP 2_CD cell_NN lines_NNS has_VBZ a_DT single_JJ
          copy_NN of_IN LAI_NNP strain_NN proviral_NN sequence_NN ._. The_DT TAR_NNP has_VBZ a_DT point_NN
          mutation_NN at_IN (_( C_NNP 37_CD -_: >_NN T_NN )_) ,_, which_WDT no_RB longer_RB responds_VBZ
          (_( efficiently_RB )_) to_TO Tat_NNP ._. However_RB ,_, the_DT cell_NN line_NN is_VBZ fully_RB
          capable_JJ of_IN making_VBG infectious_JJ virus_NN in_IN presence_NN of_IN TNF_NNP ,_,
          PHA_NNP ,_, PMA_NNP ,_, and_CC a_DT host_NN of_IN other_JJ stimuli_NNS ._. H_NNP 9_CD and_CC H_NNP 9_CD /_NN Tat_NNP
          cells_NNS are_VBP both_DT CD_NNP 4_CD +_NN Lymphocytic_NNP cells_NNS ,_, where_WRB H_NNP 9_CD cells_NNS
          carry_VBP a_DT control_NN integrated_VBN vector_NN without_IN the_DT Tat_NNP open_JJ
          reading_NN frame_NN ,_, and_CC H_NNP 9_CD /_NN Tat_NNP cells_NNS carry_VBP integrated_VBN Tat_NNP
          expression_NN vector_NN ._. Both_DT cell_NN lines_NNS were_VBD a_DT generous_JJ gift_NN
          of_IN George_NNP Pavlakis_NNP (_( NCI_NNP ,_, NIH_NNP )_) ._. U_NNP 1_CD is_VBZ a_DT monocytic_JJ clone_NN
          harboring_VBG two_CD copies_NNS of_IN the_DT viral_JJ genome_NN from_IN parental_JJ
          U_NNP 973_CD cells_NNS ._. All_DT cells_NNS were_VBD cultured_JJ at_IN 37_CD °_NN C_NNP up_IN to_TO 10_CD
          5_CD cells_NNS per_IN ml_NN in_IN RPMI-_NNP 1640_CD media_NNS ,_, containing_VBG 10_CD %_NN Fetal_NNP
          Bovine_NNP Serum_NNP (_( FBS_NNP )_) treated_VBN with_IN a_DT mixture_NN of_IN 1_CD %_NN
          streptomycin_NN and_CC penicillin_NN antibiotics_NNS ,_, and_CC 1_CD %_NN
          L-_NNP glutamine_NN (_( Gibco_NNP /_NN BRL_NNP )_) ._. Phytohemagglutinin-activated_NNP
          PBMC_NNP were_VBD kept_VBN in_IN culture_NN for_IN 2_CD days_NNS prior_RB to_TO addition_NN of_IN
          Tat_NNP protein_NN ._. Isolation_NNP and_CC treatment_NN of_IN PBMC_NNP were_VBD
          performed_VBN by_IN following_VBG the_DT guidelines_NNS of_IN the_DT Centers_NNPS for_IN
          Disease_NNP Control_NNP ._. Approximately_RB 5_CD ×_NN 10_CD 6_CD PBMC_NNP were_VBD used_VBN for_IN
          treatment_NN of_IN wild_JJ type_NN and_CC K_NNP 41_CD A_DT Tat_NNP mutant_JJ (_( 100_CD ng_NN /_NN ml_NN )_)
          proteins_NNS ._. After_IN an_DT initial_JJ incubation_NN for_IN one_CD hr_NN with_IN Tat_NNP
          proteins_NNS ,_, cells_NNS were_VBD washed_VBN and_CC cultured_JJ in_IN complete_JJ
          media_NNS for_IN 24_CD hrs_NNS ,_, prior_RB to_TO western_JJ blots_NNS ._. pCEP_NN 4_CD ,_, eTat_NN
          cells_NNS were_VBD HeLa_NNP cells_NNS stably_RB transfected_JJ with_IN either_DT a_DT
          backbone_NN control_NN plasmid_NN (_( pCEP_NN 4_CD ;_: Invitrogen_NNP )_) or_CC a_DT plasmid_NN
          expressing_VBG Tat_NNP (_( 1_CD -_: 86_CD )_) with_IN a_DT C-_NNP terminal_NN epitope_NN tag_NN
          (_( eTat_NN )_) [_NN 103_CD ]_NN ._. HeLa_NNP cell_NN lines_NNS containing_VBG either_CC the_DT
          control_NN or_CC eTat_NN plasmid_NN were_VBD selected_VBN by_IN single-cell_JJ
          dilution_NN ._. Both_DT cell_NN types_NNS were_VBD selected_VBN and_CC maintained_VBN
          under_IN 200_CD μg_NN of_IN hygromycin_NN per_IN ml_NN ._. Verification_NNP of_IN Tat_NNP
          transcriptional_NN activity_NN was_VBD achieved_VBN by_IN electroporation_NN
          of_IN reporter_NN plasmids_NNS as_RB previously_RB described_VBD [_NN 103_CD ]_NN
          ._.
        
        
          Cell_NNP cycle_NN analysis_NN
          Hela_NNP cells_NNS were_VBD blocked_VBN with_IN hydroxyurea_NN (_( Hu_NNP )_) (_( 2_CD mM_NN )_)
          for_IN 14_CD h_NN ._. Following_VBG the_DT block_NN ,_, cells_NNS were_VBD released_VBN by_IN
          being_VBG washed_VBN twice_RB with_IN phosphate-buffered_JJ saline_NN (_( PBS_NNP )_)
          and_CC by_IN the_DT addition_NN of_IN complete_JJ medium_NN ._. All_DT suspension_NN
          cells_NNS were_VBD treated_VBN with_IN 1_CD %_NN serum_NN for_IN 48_CD hrs_NNS prior_RB to_TO
          addition_NN of_IN Hu_NNP ._. Supernatants_NNP were_VBD collected_VBN and_CC analyzed_VBN
          by_IN an_DT IL-_NNP 8_CD ELISA_NNP according_VBG to_TO the_DT manufacturer_NN 's_POS
          instructions_NNS (_( Biosource_NNP International_NNP )_) ._. For_IN controls_NNS ,_,
          each_DT sample_NN ,_, approximately_RB 1_CD ×_NN 10_CD 6_CD cells_NNS was_VBD processed_VBN
          for_IN cell_NN sorting_VBG ._. Cells_NNP were_VBD washed_VBN with_IN PBS_NNP and_CC fixed_VBN by_IN
          addition_NN of_IN 500_CD μl_NN of_IN 70_CD %_NN ethanol_NN ._. For_IN
          fluorescence-activated_JJ cell_NN sorting_VBG (_( FACS_NNP )_) analysis_NN ,_,
          cells_NNS were_VBD stained_JJ with_IN a_DT cocktail_NN of_IN propidium_NN iodide_NN
          (_( PI_NNP )_) buffer_NN (_( PBS_NNP with_IN Ca_MD 2_CD +_NN and_CC Mg_NNP 2_CD +_NN ,_, RNase_NNP A_DT [_NN 10_CD μg_NN /_NN ml_NN ]_NN ,_,
          NP-_NNP 40_CD [_NN 0_CD ._. 1_LS %_NN ]_NN ,_, and_CC PI_NNP [_NN 50_CD μg_NN /_NN ml_NN ]_NN )_) followed_VBN by_IN cell-sorting_JJ
          analysis_NN ._. FACS_NNP data_NNS acquired_VBN were_VBD analyzed_VBN by_IN ModFit_NNP LT_NNP
          software_NN (_( Verity_NNP Software_NNP House_NNP ,_, Inc_NNP ._. )_) ._.
        
        
          Cell_NNP extract_VB preparation_NN and_CC immunoblotting_VBG
          All_DT cells_NNS were_VBD cultured_JJ to_TO mid-log_JJ phase_NN of_IN growth_NN ,_,
          washed_VBN with_IN PBS_NNP without_IN Ca_MD 2_CD +_NN and_CC Mg_NNP 2_CD +_NN ,_, and_CC lysed_JJ in_IN a_DT
          buffer_NN containing_VBG 50_CD mM_NN Tris-_NNP HCl_NNP (_( pH_NN 7_CD ._. 5_LS )_) ,_, 120_CD mM_NN NaCl_NNP ,_, 5_CD
          mM_NN EDTA_NNP ,_, 50_CD mM_NN NaF_NNP ,_, 0_CD ._. 2_CD mM_NN Na_NNP 
          3_CD VO_NNP 
          4_CD ,_, 1_CD mM_NN DTT_NNP ,_, 0_CD ._. 5_CD %_NN NP-_NNP 40_CD and_CC protease_NN
          inhibitors_NNS (_( Protease_NNP inhibitor_NN cocktail_NN tablets_NNS ,_,
          Boehringer_NNP Mannheim_NNP ,_, one_CD tablet_NN per_IN 50_CD ml_NN )_) ._. The_DT lysate_NN
          was_VBD incubated_JJ on_IN ice_NN for_IN 15_CD min_NN ,_, and_CC microcentrifuged_JJ at_IN
          4_CD °_NN C_NNP for_IN 10_CD min_NN ._. Total_JJ cellular_JJ protein_NN was_VBD separated_JJ on_IN
          4_CD -_: 20_CD %_NN Tris-glycine_NNP gels_NNS (_( Novex_NNP ,_, Inc_NNP ._. )_) and_CC transferred_VBN to_TO
          a_DT polvinylidene_NN difluoride_NN (_( PVDF_NNP )_) membranes_NNS (_( Immobilon-_NNP P_NN
          transfer_NN membranes_NNS ;_: Millipore_NNP Corp_NNP ._. )_) overnight_JJ at_IN 0_CD ._. 08_CD A_DT ._.
          Following_VBG the_DT transfer_NN ,_, blots_NNS were_VBD blocked_VBN with_IN 5_CD %_NN
          non-fat_JJ dry_JJ milk_NN in_IN 50_CD ml_NN of_IN TNE_NNP 50_CD (_( 100_CD mM_NN Tris-_NNP Cl_NNP [_NN pH_NN
          8_CD ._. 0_CD ]_NN ,_, 50_CD mM_NN NaCl_NNP ,_, 1_CD mM_NN EDTA_NNP )_) plus_CC 0_CD ._. 1_CD %_NN NP-_NNP 40_CD ._. Membranes_NNP
          were_VBD probed_JJ with_IN a_DT 1_CD :_: 200_CD -_: 1_CD :_: 1000_CD dilution_NN of_IN antibodies_NNS at_IN
          4_CD °_NN C_NNP overnight_JJ ,_, followed_VBN by_IN three_CD washes_NNS with_IN TNE_NNP 50_CD plus_CC
          0_CD ._. 1_CD %_NN NP-_NNP 40_CD ._. All_DT antibodies_NNS used_VBN in_IN this_DT study_NN were_VBD
          purchased_VBN from_IN Santa_NNP Cruz_NNP Biotechnology_NNP ._. The_DT next_JJ day_NN ,_,
          blots_NNS were_VBD incubated_JJ with_IN 10_CD ml_NN of_IN 125_CD I-_NNP protein_NN G_NNP
          (_( Amersham_NNP ,_, 50_CD μl_NN /_NN 10_CD ml_NN solution_NN )_) in_IN TNE_NNP 50_CD plus_CC 0_CD ._. 1_CD %_NN
          NP-_NNP 40_CD for_IN 2_CD hrs_NNS at_IN 4_CD °_NN C_NNP ._. Finally_RB ,_, blots_NNS were_VBD washed_VBN twice_RB
          in_IN TNE_NNP 50_CD plus_CC 0_CD ._. 1_CD %_NN NP-_NNP 40_CD and_CC placed_VBN on_IN a_DT PhosphorImager_NNP
          cassette_NN for_IN further_JJ analysis_NN ._.
        
        
          Total_NNP RNA_NNP purification_NN
          Cells_NNP were_VBD grown_VBN to_TO mid-log_JJ phase_NN of_IN growth_NN (_( 5_CD ._. 0_CD ×_NN 10_CD
          6_CD )_) ,_, pelleted_JJ ,_, and_CC washed_VBD twice_RB with_IN cold_JJ D-PBS_NNP without_IN Ca_MD
          2_CD +_NN /_NN Mg_NNP 2_CD +_NN ._. Total_NNP RNA_NNP was_VBD extracted_VBN on_IN ice_NN using_VBG Trizol_NNP
          Reagent_NNP (_( Life_NNP Technologies_NNPS ,_, Inc_NNP ._. )_) ._. Purified_NNP RNA_NNP was_VBD then_RB
          analyzed_VBN on_IN a_DT 1_CD %_NN agarose_NN gel_NN for_IN quality_NN and_CC quantity_NN
          prior_RB to_TO each_DT experiment_NN ._.
        
        
          Glass_NN slide_NN microarray_NN
          Gene_NNP expression_NN analysis_NN was_VBD performed_VBN using_VBG
          Micromax_NNP ™_NN :_: Human_NNP cDNA_NN Microarray_NNP System_NNP I_PRP (_( cat_NN #_# MPS_NNP 101_CD ,_,
          NEN_NNP Life_NNP Science_NNP Products_NNPS )_) ._. On_IN a_DT glass_NN microarray_NN slide_NN ,_,
          2400_CD know_VB human_JJ genes_NNS were_VBD arrayed_JJ into_IN 4_CD separate_JJ grids_NNS
          (_( A_DT ,_, B_NNP ,_, C_NNP ,_, D_NNP )_) ,_, containing_VBG 600_CD genes_NNS each_DT (_( gene_NN description_NN
          and_CC location_NN on_IN microarrays_NNS available_JJ at_IN NEN_NNP website_NN :_:
          www_NN ._. nenlifesci_NN ._. com_NN )_) ._. All_DT human_JJ genes_NNS were_VBD ~_NN 2200_CD bp_NN cDNAs_NNS ,_,
          and_CC were_VBD characterized_VBN from_IN 50_CD +_NN human_JJ cDNA_NN libraries_NNS
          (_( AlphaGene_NNP ,_, Inc_NNP ._. ,_, Woburn_NNP ,_, MA_NNP )_) ._. In_IN addition_NN to_TO the_DT human_JJ
          genes_NNS ,_, three_CD plant_NN control_NN genes_NNS were_VBD spotted_VBN on_IN each_DT
          grid_NN and_CC were_VBD utilized_JJ to_TO balance_VB the_DT Cyanine-_NNP 3_CD (_( Cy-_NNP 3_LS )_)
          and_CC Cyanine-_NNP 5_CD (_( Cy-_NNP 5_LS )_) fluorescence_NN signals_NNS ._.
          A_DT total_NN of_IN 8_CD μg_NN each_DT of_IN H_NNP 9_CD (_( control_NN sample_NN )_) and_CC H_NNP 9_CD /_NN Tat_NNP
          (_( test_NN sample_NN )_) mRNAs_NNS were_VBD reverse_VB transcribed_JJ into_IN Biotin_NNP
          and_CC Dinitrophenyl_NNP (_( DNP_NNP )_) labeled_VBN cDNA_NN ,_, respectively_RB ._. After_IN
          cDNA_NN quality_NN and_CC quantities_NNS were_VBD analyzed_VBN ,_, both_DT cDNAs_NNS
          were_VBD then_RB pooled_VBN and_CC simultaneously_RB hybridized_JJ overnight_JJ
          at_IN 65_CD °_NN C_NNP onto_IN the_DT glass_NN microarray_NN ._. The_DT next_JJ day_NN ,_, the_DT
          microarray_NN slide_NN was_VBD serially_RB washed_VBN in_IN 0_CD ._. 5_CD ×_NN SSC_NNP (_( Sodium_NNP
          Citrate-_NNP Sodium_NNP Chloride_NNP )_) +_NN 0_CD ._. 01_CD %_NN SDS_NNP (_( Sodium_NNP Dodecyl_NNP
          Sulfate_NNP )_) ,_, 0_CD ._. 06_CD ×_NN SSC_NNP +_NN 0_CD ._. 01_CD %_NN SDS_NNP ,_, and_CC 0_CD ._. 06_CD ×_NN SSC_NNP ._. Next_JJ ,_, the_DT
          Tyramide_NNP Signal_NNP Amplification_NNP (_( TSA_NNP ™_NN )_) was_VBD then_RB used_VBN to_TO
          amplify_VB the_DT Cy-_NNP 3_CD and_CC Cy-_NNP 5_CD signals_NNS using_VBG antibody-enzyme_JJ
          conjugates_NNS ,_, α-_NN DNP-Horseradish_NNP peroxidase_NN (_( HRP_NNP )_) and_CC
          α-_NN Streptavidin-_NNP HRP_NNP with_IN Tyramide_NNP linked_VBD Cy-_NNP 3_CD and_CC Cy-_NNP 5_CD ._.
          Screening_NNP and_CC data_NNS analysis_NN was_VBD performed_VBN by_IN NEN_NNP ._.
        
        
          cDNA_NN filter_NN hybridization_NN
          Gene_NNP expression_NN of_IN CEM_NNP and_CC ACH_NNP 2_CD were_VBD performed_VBN using_VBG
          Atlas_NNP Human_NNP cDNA_NN Expression_NNP Array_NNP (_( Clontech_NNP Laboratories_NNPS
          Inc_NNP ._. ,_, Palo_NNP Alto_NNP ,_, CA_NNP )_) according_VBG to_TO the_DT manufacturer_NN 's_POS
          directions_NNS ._. One_CD μg_NN of_IN poly_RB A_DT +_NN RNA_NNP each_DT was_VBD DNase_NNP I_PRP
          treated_VBD ,_, purified_JJ using_VBG a_DT CHROMA_NNP SPIN-_NNP 200_CD column_NN ,_, and_CC
          reverse_VB transcribed_JJ into_IN 32_CD P-_NNP labeled_VBD cDNA_NN ._. The_DT CHROMA_NNP
          SPIN-_NNP 200_CD column_NN was_VBD used_VBN to_TO purify_NN the_DT 32_CD P-_NNP labeled_VBD cDNA_NN
          from_IN unincorporated_JJ 32_CD P-_NNP labeled_VBD dNTPs_NNS and_CC small_JJ (_( <_NN 0_CD ._. 1_LS
          kb_NN )_) cDNA_NN fragments_NNS ._. Each_DT sample_NN was_VBD then_RB hybridized_JJ to_TO a_DT
          human_JJ cDNA_NN expression_NN array_NN overnight_JJ with_IN continuous_JJ
          agitation_NN at_IN 68_CD °_NN C_NNP ._. The_DT next_JJ day_NN ,_, the_DT array_NN was_VBD washed_VBN
          three_CD times_NNS with_IN gentle_JJ agitation_NN ,_, first_JJ wash_NN with_IN 2_CD ×_NN SSC_NNP
          +_NN 1_CD %_NN SDS_NNP and_CC the_DT last_JJ two_CD washes_NNS with_IN 0_CD ._. 1_CD ×_NN SSC_NNP +_NN 0_CD ._. 5_CD %_NN SDS_NNP
          at_IN 37_CD °_NN C_NNP ._. Array_NNP was_VBD exposed_VBN to_TO a_DT PhosphorImager_NNP Cassette_NNP
          and_CC analyzed_VBD using_VBG ImageQuant_NNP software_NN ._.
        
        
          Northern_JJ blots_NNS
          Total_JJ cellular_JJ RNA_NNP was_VBD extracted_VBN using_VBG the_DT RNAzol_NNP
          reagent_NN (_( Gibco_NNP /_NN BRL_NNP )_) ._. Total_NNP RNA_NNP (_( 20_CD μg_NN )_) was_VBD isolated_VBN from_IN
          various_JJ cells_NNS and_CC ran_VBD on_IN a_DT 1_CD %_NN formaldehyde-agarose_JJ gel_NN
          overnight_JJ at_IN 75_CD V_NNP ,_, transferred_VBN onto_IN a_DT 0_CD ._. 2_CD μm_NN
          nitrocellulose_NN membrane_NN (_( Millipore_NNP Inc_NNP ._. )_) ,_, UV_NNP
          cross-linked_JJ ,_, and_CC hybridized_JJ overnight_JJ at_IN 42_CD °_NN C_NNP with_IN
          32_CD P-_NNP end-labeled_JJ 40_CD mer_NN oligo_NN probes_NNS including_VBG p_NN 21_CD /_NN Waf_NNP 1_CD ,_,
          C-_NNP myc_NN ,_, Pro-thymosin_NNP ,_, Actin_NNP ,_, Tat_NNP ,_, and_CC Ubiquitin_NNP
          (_( Loftstrand_NNP ,_, Gaithersburg_NNP ,_, Md_NNP ._. )_) ._. Next_JJ day_NN ,_, membranes_NNS were_VBD
          washed_VBN two_CD times_NNS for_IN 15_CD min_NN each_DT ,_, with_IN 10_CD ml_NN of_IN 0_CD ._. 2_CD %_NN
          SDS-_NNP 2_CD XSSC_NNP at_IN 37_CD °_NN C_NNP ,_, exposed_VBN ,_, and_CC counted_VBD on_IN PhosphorImager_NNP
          Cassette_NNP ._.
        
        
          Viral_NNP infection_NN and_CC ELISA_NNP assay_NN
          Both_DT H_NNP 9_CD and_CC H_NNP 9_CD /_NN Tat_NNP cells_NNS were_VBD infected_JJ in_IN the_DT presence_NN
          of_IN 10_CD ug_NN of_IN polybrene_NN ._. For_IN PBMC_NNP infections_NNS ,_, PHA_NNP activated_VBN
          PBMCs_NNP were_VBD kept_VBN in_IN culture_NN for_IN 2_CD days_NNS prior_RB to_TO each_DT
          infection_NN ._. Isolation_NNP and_CC treatment_NN of_IN PBMCs_NNP were_VBD
          performed_VBN by_IN following_VBG guidelines_NNS from_IN the_DT CDC_NNP
          (_( Isolation_NNP ,_, culture_NN ,_, and_CC identification_NN of_IN HIV_NNP ,_,
          Procedural_NNP Guide_NNP ,_, July_NNP 1991_CD ,_, Atlanta_NNP ,_, GA_NNP )_) ._. Approximately_RB
          2_CD ×_NN 10_CD 6_CD of_IN H_NNP 9_CD or_CC H_NNP 9_CD /_NN Tat_NNP cells_NNS ,_, and_CC 5_CD ×_NN 10_CD 6_CD PBMC_NNP cells_NNS
          were_VBD infected_VBN with_IN either_DT an_DT HXB-_NNP 2_CD (_( CXCR_NNP 4_CD ,_, T-_NNP tropic_JJ )_) ,_, or_CC
          BaL_NNP (_( CCR_NNP 5_CD ,_, Macrophage-tropic_NNP )_) at_IN 5_CD ng_NN of_IN p_NN 24_CD gag_NN antigen_NN /_NN
          HIV-_NNP 1_CD strain_NN ._. Both_DT viral_JJ isolates_VBZ were_VBD obtained_VBN from_IN the_DT
          NIH_NNP AIDS_NNP research_NN and_CC reference_NN reagent_NN program_NN ._. After_IN 8_CD
          hrs_NNS of_IN infection_NN ,_, cells_NNS were_VBD washed_VBN and_CC fresh_JJ media_NNS was_VBD
          added_VBN ._. Samples_NNP were_VBD collected_VBN every_DT 3_CD rdday_NN and_CC stored_VBD at_IN
          -_: 20_CD C_NNP for_IN p_NN 24_CD gag_NN ELISA_NNP ._. Media_NNP from_IN HIV-_NNP 1_CD infected_JJ cells_NNS
          were_VBD centrifuged_JJ to_TO pellet_NN the_DT cells_NNS and_CC supernatants_NNS
          were_VBD collected_VBN ,_, and_CC diluted_VBD to_TO 1_CD :_: 100_CD to_TO 1_CD :_: 1000_CD in_IN RPMI_NNP
          1640_CD prior_RB to_TO ELISA_NNP ._. The_DT p_NN 24_CD gag_NN antigen_NN level_NN was_VBD
          analyzed_VBN by_IN HIVAG_NNP ™_NN -_: 1_CD Monoclonal_NNP antibody_NN Kit_NNP (_( Abbott_NNP
          Laboratories_NNPS ,_, Diagnostics_NNPS Division_NNP )_) ._.
        
      
      
        Authors_NNP '_'' Contributions_NNP
        CF_NNP ,_, and_CC FS_NNP carried_VBD out_RP the_DT ACH_NNP 2_CD and_CC H_NNP 9_CD /_NN Tat_NNP microarrays_NNS ._.
        LD_NNP ,_, CE_NNP ,_, IZ_NNP ,_, CGL_NNP ,_, and_CC KW_NNP aided_VBD in_IN westerns_NNS ,_, northerns_NNS ,_, p_NN 24_CD
        and_CC ELISA_NNP assays_NNS ._. AM_NNP ,_, KK_NNP ,_, SB_NNP ,_, AP_NNP ,_, and_CC FK_NNP aided_VBD in_IN data_NNS
        interpretation_NN ,_, Bioinformatics_NNP ,_, literature_NN searches_NNS and_CC
        writing_VBG the_DT manuscript_NN ._.
      
    
  
